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ABSTRACT 
 
In photodynamic therapy a photosensitizer drug is administered and is irradiated with light. Upon 
absorption of light the photosensitizer goes into its triplet state and transfers energy or an 
electron to oxygen to form reactive oxygen species (ROS). These ROS react with biomolecules 
in cells leading to cell damage and cell death. PDT has interested many researchers because of its 
non-invasiveness as compared to surgery, it leaves little to no scars, it is time and costs effective, 
it has potential for targeted treatment, and can be repeated as needed. A number of 
photosensitizers have been approved by the FDA for clinical application of PDT. PDT is 
currently used in early-stage cancers of the head and neck, in treating advanced cancer by 
shrinking the tumor, basal cell skin cancer, and Bowen’s disease among others. Research is 
currently in progress to improve the optical properties and clinical applicability of 
photosensitizers.   
Different photosensitizers such as porphyrines, chlorophylls, and dyes have been used in PDT to 
treat various cancers, skin diseases such as acne vulgaris, aging and sun-damaged skin. 
Historically, these have been divided into first and second generation sensitizers. Low extinction 
coefficients, presence of impurities, and skin phototoxicity were characteristic for first 
generation sensitizers. With the second generation of sensitizers, which include Porphyrins, 
Chlorophylls, Bacteriopheophorbides, Texaphyrins, Phtalocyanines, and dyes such as 
Anthraquinones, Rose Bengal, and Methylene Blue, attempts were made to improve upon these 
issues. Skin sensitivity was reduced and extinction coefficients were brought up to ~ 10
5
 L mol
-1
 
cm
-1
. The porphyrine family is comprised of photosensitizers such as HpD (hematoporphyrin 
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derivative), BPD (benzoporphyrin derivative), ALA (5-aminolevulinic acid), Vertiporfin, and 
Texaphyrins. The Chlorophylls group of photosensitizers, prepared from base of purple bacteria 
and blue-green algae, includes Chlorins, Purpurins and Bacteriochlorins and show deep red 
absorption. Dyes such as Phtalocyanine, Napthalocyanine, Rose Bengal, and Methylene Blue are 
often used as photosensitizers as well. While PDT based on these small molecule 
photosensitizers has shown great promise, only a handful (mainly Photofrin, ALA, Vertiporfin, 
and Phthalocyanine) have been clinically approved. The main issues with current sensitizers are 
(i) hydrophobicity leading to aggregation in aqueous media resulting in reduced efficacy and 
potential toxicity, (ii) dark toxicity of photosensitizers, (iii) non-selectivity towards malignant 
tissue resulting in prolonged cutaneous photosensitivity and damage to healthy tissue, (iv) 
limited light absorption efficiency, and (v) a lack of understanding of where the photosensitizer 
ends up in the tissue.   
In this dissertation research program, these issues were addressed by the development of 
conducting polymer nanoparticles as a next generation of photosensitizers. This choice was 
motivated by the fact that conducting polymers have large extinction coefficients (> 10
7
 L mol
-1
 
cm
-1
), are able to undergo intersystem crossing to the triplet state, and have triplet energies that 
are close to that of oxygen. It was therefore hypothesized that such polymers could be effective 
at generating ROS due to the large excitation rate that can be generated. The hydrophobicity of 
these polymers was hypothesized to be able to contribute to the fabrication of conducting 
polymer nanoparticles that are dispersible and stable in aqueous media. The resulting organic 
nanoparticles were expected to exhibit reasonable biocompatibility (in dark) due to the absence 
of impurities, heavy metals, or redox active moieties. Targeting of these conducting polymer 
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nanoparticles was hypothesized to be feasible based on the development of blended nanoparticles 
containing amphiphilic polymers with chemically active moieties. Finally, these conducting 
polymers are brightly fluorescent, which lead to the hypothesis that this property may allow for 
facile in-vitro localization and tracking.    
First, conducting polymer nanoparticles (CPNPs) composed of the conducting polymer poly[2-
methoxy-5-(2-ethylhexyl-oxy)-p-phenylenevinylene] (MEH-PPV) and 50 wt% Phenyl-C61-
butyric acid methyl ester (PCBM) were fabricated and characterized together with the 
corresponding undoped (pure MEH-PPV) nanoparticles. The addition of PCBM was 
hypothesized to result in greater efficiency of ROS generation by ultrafast charge transfer from 
MEH-PPV to PCBM. The nanoparticles were fabricated by reprecipitation method, in which 
MEH-PPV polymer or mixed MEH-PPV/PCBM solution in THF (tetrahydrofuran) is injected in 
water. THF was selected as solvent due to its miscibility with water and good solubility of MEH-
PPV and PCBM in THF. Due to its hydrophobic properties the polymer aggregates with itself 
when exposed to water to self-assemble into nanoparticles. These nanoparticles remain 
suspended in water and are well dispersed. The nanoparticles were found to be stable in buffer 
and culture media. Both types of nanoparticles were found to exhibit no cytotoxicity in dark, 
however, human breast cancer cell lines did exhibit dark toxicity at the highest NP dose used 
herein for the MEH-PPV/PCBM nanoparticles. Due to this observation, together with quenched 
fluorescence emission of MEH-PPV due to the presence of PCBM, and the limited potential of 
clinical application of fullerenes these blended nanoparticles were not considered further after 
initial study. Selectivity of nanoparticle uptake was studied by fluorescence microscopy and flow 
cytometry. Although not fully selective, the nanoparticles exhibited a strong bias to the cancer 
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cells, which is attributed to the hydrophobicity of the nanoparticles and aggressiveness of cancer 
cells with respect to normal cells. For the cancer cell lines studied, uptake increased from MDA-
MB-231 followed by A549 to OVCAR3. The formation of ROS was proven in-vitro by staining 
of the cells with CellROX Green Reagent, after which PDT results were quantified by MTT 
assays. Cell mortality was observed to scale with nanoparticle dosage and light dosage. Cell 
death was observed for the complete OVCAR3 population treated by NPs, and mainly proceed 
by apoptosis. In general, the fullerene doped NPs were found to be almost 30 % more effective 
than the undoped CPNPs, but these NPs were not considered further after these studies for 
reasons given above.   
Second, the MEH-PPV nanoparticles were developed further to allow for surface 
functionalization, with the aim of targeting these NPs to specific cancer cell lines as determined 
by the ligand that is conjugated. This task was accomplished by blending MEH-PPV with 
Polystyrene Graft Ethylene Oxide with carboxylic acid (PS-PEG-COOH) into nanoparticles. It 
was hypothesized that the hydrophobic block of the PS-PEG-COOH polymer would integrate 
with the nanoparticle core, while the hydrophilic block would remain on the surface and extend 
into the aqueous media. Folic acid was successfully conjugated to MEH-PPV/PS-PEG-COOH 
nanoparticles (MPNPs) as the targeting ligand by EDC chemistry with the aim to selectively 
target cancer cells that overexpress folate receptors (FR). These functionalized nanoparticles 
(FNPs) were studied in OVCAR3 (ovarian cancer cell line) as FR+, MIA PaCa2 (pancreatic 
cancer cell line) as FR-, and A549 (lung cancer cell line) having marginal FR expression. 
Complete selectivity of the FNPs towards the FR+ cell line was found, and is attributed to the 
hydrophobicity and large negative zeta potential of the nanoparticles, which reduces the 
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statistical probability of non-specific uptake to virtually zero. The abundant uptake of the FNPs 
by the FR+ cell line (OVCAR3) compared to the marginal uptake of FNPs by the cell line with 
marginal FR expression (A549) further confirms the selectivity of the FNPs due to the 
aforementioned properties as well as being due to the receptor mediated uptake mechanism. 
Quantification of PDT results by MTS assays and flow cytometry show that PDT treatment was 
fully selective to the FR+ cell line (OVCAR3). No cell mortality was observed for the other cell 
lines studied here within experimental error.    
Finally, the issue of confirming and quantifying small molecule drug delivery to diseased tissue 
was tackled by developing quantum dot (Qdot) biosensors. Initially, a 
multifunctional/multimodal composite activatable nanoprobe (MMCNP) was developed, with 
the aim to enable magnetic resonance imaging (MRI) for MMCNP tracking and fluorescence 
reporting of intracellular small molecule/drug delivery. It was hypothesized that MRI activity 
could be achieved with the integration of paramagnetic ironoxide core nanoparticles, while 
fluorescence reporting could be achieved by attaching functionalized Qdots to the ironoxide core 
nanoparticle. For fluorescence reporting prior expertise in control of the fluorescence state of 
Qdots was employed, where redox active ligands can place the Qdot in a quenched OFF state. 
Ligand attachment, including folic acid for targeting and STAT3 anticancer drug, was 
accomplished by disulfide linker chemistry, which was hypothesized to be reversible in the 
presence of sulfur reducing biomolecules, resulting in Qdots in a brightly fluorescent ON state. 
Glutathione (GSH) is such a biomolecule that is present in the intracellular environment. 
Experimental data shows that this design was successfully implemented. Fluorescence 
restoration of Qdots was observed in the intracellular environment of cancer cells confirming 
vii 
 
delivery of ligands including STAT3 anticancer drug, the MMCNPs showed targeted uptake by 
cancer cell lines, MRI activity was proven in a phantom, and cancer cell viability was reduced by 
30% with respect to the control. In addition, the MMCNP facilitated targeted delivery of the 
STAT3 anticancer drug, so that a 15% improvement in treatment efficiency was observed 
compared to treatment with free drug.   
An updated biosensor probe was recently developed to both confirm delivery of small 
molecule/drug to intracellular and quantify the amount of drug delivered. For fluorescence 
reporting of the delivery event prior expertise in control of the fluorescence state of Qdots was 
employed again, where the redox active dopamine ligands placed the Qdot surface as quenchers 
OFF state). Since the Qdot fluorescence restoration was found to be dependent on the amount of 
ligands removed from the Qdot surface, the probe was designed to allow for ratiometric 
quantification. A folic acid (targeting) and dye (ratiometric standard) labeled chitosan shell was 
fabricated on the dopamine/cargo functionalized Qdot surface. It was hypothesized that a 
ratiometric measurement of the fluorescence of Qdot (changing with the amount of cargo 
released) with respect to the constant emission of a dye in the chitosan shell could provide a 
quantitative measurement of the cargo released in the cells. Current experimental work shows 
that the quenching of Qdot fluorescence occurs through an electron transfer process from or to 
the Qdots depending on conjugation of the oxidized (quinone) form of dopamine or reduced 
(catechol) form of the dopamine, respectively, as revealed from single particle spectroscopy data. 
Epiluminescence imaging to determine uptake of the probe showed limited internalization of the 
probe by the cell lines due to aggregation of the probe in the aqueous media, together with the 
absence of dopamine receptors on the membranes of cell lines studied herein (A549 and 
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OVCAR3). However, Restoration of Qdot fluorescence due to displacement of dopamine with 
intracellular GSH was observed in the cells. Though the uptake of the probe was limited, the 
intracellular single particle spectroscopy data collected on cells that have internalized the probe, 
give a promising proof of concept.  
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SUMMARY 
 
The dissertation will have 6 chapters including introduction as the first chapter. The first chapter 
contains background and significance of the research. It gives a background on Photodynamic 
therapy, its mechanism of treating the diseases, its disadvantages and problems. In significance, a 
discussion on how these problems have been tackled with conducting polymer nanoparticles is 
covered. Chapter 2 comprises the instrumentation and experimental discussion for the methods 
used in this dissertation research. Chapter 3 is consists of the observations made on using PCBM 
doped MEH-PPV nanoparticle for PDT on various cancer cell lines. In chapter 4 PDT using 
undoped MEH-PPV nanoparticles is discussed. Chapter 5 shows the functionalization of MEH-
PPV nanoparticles and targeted photodynamic therapy. And chapter 6 has the results obtained 
during the development of a Qdot-dopamine biosensor for quantifying drug delivery in cells. 
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 SIGNIFICANCE AND BACKGROUND CHAPTER 1
 
  Background 1.1
 
 1.1.1  Statistical surveys on cancer 
 
The American Society of Clinical Oncology (ASCO) has come up with a cancer progress 
timeline since the first chemotherapy in 1949 including the new targeted treatments for nearly 
120 types of cancers [1]. As shown in Figure 1.1A, the nation’s cancer death has reduced by 18% 
since 1990 after the continuous increase. This is due to the advances in every area of cancer 
treatment such as prevention, screening, chemotherapy, radiotherapy, surgery, and recently the 
targeted treatments. Also the improved managements in side effects after the treatment enabled 
patients to live better lives. The percent of patients surviving at least for 5 years after the 
diagnosis of cancer has also increased gradually throughout these years (Figure 1.1B), though the 
number of cases of cancer is still increasing (Figure 1.1C). More recent statistics on survival of 
cancer adapted from the American Cancer Society's publication, Cancer Facts & Figures 2014, 
and the National Cancer Institute Office of Cancer Survivorship showed that the number of 
people with a history of cancer in the United States has increased dramatically, from 3 million in 
1971 to about 13.7 million today. Of these, an estimated 379,112 are survivors of childhood and 
adolescent cancer, which means they were diagnosed before the age of 20. About 68% of today’s 
cancer survivors were diagnosed with cancer five or more years ago. And, approximately 15% of 
all cancer survivors were diagnosed 20 or more years ago. More than half of cancer survivors are 
65 or older. An estimated 1 in 530 adults between the ages of 20 and 39 is a survivor of 
childhood cancer.  
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Figure 1.1 A) mortality of cancer patients through 1970-2010 showing decrease in death of 
cancer patients, B) percent of patients surviving for five years increase through 1970-2010, C) 
new cases of cancer still increasing.  
 
The increase in survival percent throughout these years can be attributed to improved diagnostic 
methods, improvements in treatments, better management of side effects and new targeted 
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therapies. The SEER stat fact sheets released by National Cancer Institute show that even if the 
pancreatic cancer is only 2.8% (number of patients - 46, 420) of all new cancer cases in 2014, the 
estimated survival of patients with pancreatic cancer is only 6.7 [2]. They have found that liver 
cancer is only 2 % of all the new cancer cases (number of patients – 33,190), while the estimated 
survival rate is 16.6 %. The lung cancer is 13.5 % of all new cases and the survival is as low as 
the liver cancer. Thus even if fight against cancer is improving throughout these years, there are 
still some types of cancers that need more research to have a safer and effective treatment.  
 
 1.1.2  Available treatments for cancer 
 
Various treatments of cancer include surgery [3, 4], radiotherapy [5, 6], and chemotherapy [7-
11]. Surgery can be done by different methods. Most of the surgeries follow radiotherapy or 
chemotherapy to remove the remaining cancer cells after surgery. Some common types of 
surgery are 1) cryosurgery in which cold material such as liquid nitrogen spray or cold probe is 
used to freeze the cells and destroy them.[12], 2) electrosurgery in which high-frequency electric 
currents are given, 3) laser surgery in which high intensity light is used to shrink or vaporize the 
cancer cells, 4) Mohs surgery in which cancer cells at sensitive areas such as eye, skin are 
removed layer by layer until all the cancerous tissue has been removed, 5) laparoscopic surgery 
in which laparoscope is used to see inside the body. Many small incisions are made and a tiny 
camera is inserted in the body, 6) natural orifice surgery in which surgical tools are passed 
through a natural body opening such as mouth, rectum or vagina, 7) robotic surgery in which the 
surgeon uses hand controls that tell a robot how to use surgical tools for operation. This helps the 
surgeon to operate areas which are hard to reach. Developments have been made in surgery 
techniques by using lasers [13-17] and fluorescence imaging guided surgery [18, 19]. In laser 
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surgery 63 patients with tracheobronchial tumors were treated with lasers to burn the tumor 
tissue. The results were very impressive as shown in Table 1.1 [20] 
Table 1.1 Results for surgery using laser beam [20] 
 
 
In fluorescence imaging guided surgery 139 out of 270 patients were randomly assigned with 20 
mg/kg bodyweight 5-aminolevulinic acid (5-ALA) which is non-fluorescent prodrug that leads to 
intracellular accumulation of fluorescent porphyrins in malignant glioma. After resection on the 
139 patients (assigned to 5 ALA) and the remaining 131 patients (assigned to white light) a 
survey was done after 6 months for progression-free survival. They observed that the tumor was 
completely resected in 90 patients (65%) of 139 who were assigned with 5-ALA, while only 47 
patients (36%) of 131 assigned with white light had the tumor completely resected [18]. The total 
results are shown in Figure 1.2.  
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Figure 1.2 Progression-free survival after resection in 5-ALA assigned (red line) and white light 
assigned (black light) patients.[18]  
 
An example of intraoperative near infrared fluorescence imaging surgery is to give breast cancer 
patients 
99m
Tc-sulfur colloid lymphoscintigraphy followed by 12.5 µg of indocyanine green 
(ICG) diluted in human serum albumin (HSA) as NIR fluorescent lymphatic tracer. 
 
Figure 1.3 Breast Cancer Sentinel Lymph Nodes Mapping and resection using NIR fluorescence 
imaging guided surgery.[19] 
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Breast Cancer Sentinel Lymph Nodes were identified and resected in 9 breast cancer patients 
(Figure 1.3) [19]. 
 
 1.1.3 Recent developments of small molecule and nanoparticle anticancer drugs 
 
A lot of research has been done and is still in progress on developing drugs for effective 
treatment of cancer. The most common drugs to date to be used in cancer therapy are 
doxorubicin, paclitaxel and STAT3 inhibitors.  
 
 Small molecule drugs 1.1.3.1
 
Doxorubicin, like other anthracycline molecules intercalates with DNA and partially uncoil the 
double-stranded helix [21, 22]. Doxorubicin has high affinity for cell nuclei and as much as 60% 
of the total intracellular amount of doxorubicin is found in the nucleus. Once it is bound to DNA, 
it inhibits DNA polymerase and nucleic acid synthesis and also disrupts the topoisomerase-II-
mediated DNA repair, resulting in the formation of protein-linked DNA double strand breaks. In 
tumor cells, the anthracycline-induced perturbations result in a pathway of endonucleolytic DNA 
fragmentation known as apoptosis. Because proliferation is important of tumor growth, 
interference with the genome is the primary cause of the anti-tumor action of doxorubicin. 
Doxorubicin acts as anti-tumor drug in one other way also. It is assumed to form free radicals in 
the subcellular environment. In short, doxorubicin gets oxidized to semiquinone, an unstable 
metabolite, presumably by NADH dehyrogenases, nitric oxide synthases or xanthine oxidases, 
and is converted back to doxorubicin in a process that releases reactive oxygen species. The 
reactive oxygen species then lead to lipid peroxidation and membrane damage, DNA damage, 
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oxidative stress, and triggers apoptosis [22]. Doxorubicin has been used to treat a variety of types 
of cancer [23]. It has been used to treat cervical cancer [24], endometrical cancer [25], pancreatic 
cancer [26, 27], prostate cancer [28], head and neck cancer [29], skin cancer [28], bone cancer 
[30], lung cancer [31], breast cancer [32], stomach cancer [33], soft tissue sarcoma [28] etc.. 
The second most commonly used drug is the STAT3 inhibitors. It works by inhibiting the 
STAT3, the signal transducer and activator of transcription [34-37]. STAT3 is a transcription 
factor which plays a key role in normal cell growth [37] and is highly activated in about 70% 
cancers [35, 37].  
 
Figure 1.4 Strategies of STAT inhibition in tumor cells.[37] 
 
The activated STAT3 is phosphorylated forming a dimer which enters the nucleus via interaction 
with importins and binds target genes. Inhibition of STAT3 results in the death of tumor cells 
(Figure 1.4). STAT3 inhibitor drug has been shown to have effective results in treating various 
cancer cell lines [38]. The breast carcinoma cell lines (MDA-MB-231 and MDA-MB-435), 
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pancreatic cancer cells (Panc-1) and NIH3T3/v-Src fibroblasts showed inhibition in the growth 
when incubated with STAT3 [39]. Prostate cancer cells in-vivo showed growth inhibition and 
increased apoptosis (Figure 1.5) [40]. Though this path to fight cancer seems very easy, there are 
only a small number of STAT3 direct inhibitors. Also, the STAT1 (another STAT family 
member) which helps in apoptosis, cell death and defense against pathogens is very similar with 
STAT3. This similarity requires that STAT3-inhibitors have no effect on STAT1 [34, 36]. 
 
Figure 1.5 Apoptosis induced by STAT3 in prostate cancer cells. 
 
Paclitaxel also called as taxol is an antitumor drug which affects the microtubule formation 
during mitosis and inhibit the growth of cancer cells [41]. Microtubules are also critical for the 
performance of many important cell functions, such as maintenance of cell shape, cellular 
motility and attachment, and intracellular transport. Microtubules are always in a dynamic 
equilibrium with their basic protein subunits, tubulin dimers. Taxol promotes microtubule 
assembly and stabilizes microtubules by shifting the dynamic equilibrium toward microtubule 
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assembly [42-45]. Taxol concentrations as low as 0.05 µmol/L shift the equilibrium in favor of 
microtubule formation by decreasing the lag time for microtubule assembly [45]. This way taxol 
decreases the critical concentration of tubulin required for microtubule assembly during mitosis 
[46, 47]. Microtubules treated with taxol are stable even after treatment with calcium or low 
temperatures, conditions that usually promote disassembly [44, 45, 48]. This unusual stability 
results in inhibition of the normal dynamic reorganization of the microtubule network inhibiting 
the growth of cancer cells [49].  
 
  Nanoparticles for drug delivery 1.1.3.2
 
Most of the drugs are hydrophobic posing a problem of delivery in blood circulation. This 
reduces the efficacy of the therapeutic drug. Research has been done to deliver the hydrophobic 
drugs more efficiently by encapsulating or conjugating them in hydrophilic nanoparticles that are 
functionalized with ligands specific for receptors overexpressed on cancer cell surfaces. Figure 
1.6 shows few examples of nanoparticles which are used to encapsulate drug molecules (Figure 
1.6 A and Figure 1.6 C) or conjugated drug molecules (Figure 1.6 B) [50]. Encapsulation or 
conjugation of drug entities in nanoparticles has multiple advantages over use of the drug entity 
alone. For example, Doxorubicin Encapsulated in Polyethylene-glycol Coated Liposomes, called 
as Doxil nanoparticles have enhanced accumulation of doxorubicin and increased circulation 
time as compared to free doxorubicin [51]. 
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.  
Figure 1.6 A) Polymeric micelles encapsulating drug molecules, B) Polymers conjugated with 
drug molecules, C) liposomes encapsulating drug molecules for improved pharmacokinetics and 
pharmacodynamics by active intracellular delivery.[50]. The graph shows extended 
pharmacokinetics of nanoparticles over the therapeutic entity alone [52] 
 
 
Figure 1.7 Increased accumulation of doxorubicin when encapsulated in Doxil as compared to 
free doxorubicin.[51] 
 
 
A
B
C
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Figure 1.7 shows the increased level of doxorubicin in the body of patients when it is 
encapsulated in Doxil as compared to free doxorubicin. The increase in accumulation is due to 
the high amount of loading of drug in nanoparticles of size 80-90 nm in diameter. The PEG 
conjugated on the liposomes increases the circulation time in body. Targeted drug delivery is the 
solution to reduce the side effects and it can be achieved by encapsulating the drug entities in 
nanocarriers which are targeted towards cancer [50]. Doxorubicin encapsulated in liposome 
nanoparticles tagged with PEG and the human monoclonal antibody GAH which reacts to almost 
90 % of stomach cancer tissue but not to normal tissue was used in patients with metastatic 
stomach cancer[53]. Semiconductor quantum dots, CdSe-ZnS, encapsulated in ABC triblock 
copolymer linked with tumor-targeting ligand and PEG were used for drug delivery by Gao et al 
[54]. The probe was coated with PEG for better circulation in blood while the triblock polymer 
protects the optical properties of Qdots in a broad range of pH. Passive targeted delivery in 
prostate cancer was achieved by better circulation of the probe due to PEG. The active targeted 
delivery was achieved by conjugating the probe with prostate-specific membrane antigen 
(PSMA) monoclonal antibody. Figure 1.8 A shows the development of the probe and Figure 1.8 
B shows the uptake of the probe in human prostate cancer cells which express PSMA and cells 
which do not express PSMA. Another example of multifunctional nanoparticles for cancer 
therapeutics is reported by Liong et al. [55]. In this the superparamagnetic nanocrystals for MR 
imaging were encapsulated in silica nanoparticles. Anticancer drug was stored inside the pores in 
silica. For hydrophilicity the silica nanoparticles were coated with phosphonate coating. The 
nanoparticles were made targeted by attaching targeted ligand, folic acid. Figure 1.9 shows 
increased uptake of nanoparticles conjugated with folic acid in PANC-1 which overexpresses 
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folate receptors. In HFF cells which do not overexpress folate receptors have shown to uptake 
fewer nanoparticles.  
 
Figure 1.8 A) Development of the Qdot probe and depiction of passive (conjugated with PEG) 
and active (conjugated with PEG and PSMA antibody) tumor targeting, B) uptake of Qdot probe 
in PSMA positive cells (C4-2) and PSMA negative cells (PC-3). A negative control with Qdots 
not conjugated with PSMA antibody is also shown 
 
Figure 1.9 Uptake of silica nanoparticles in Panc-1 cells which overexpress folate receptors and 
HFF cells which have no folate receptor overexpression. 
 
 
A B
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Drugs such as paclitaxel, doxorubicin, and STAT3 inhibitor have been used to treat cancer 
through chemotherapy [24, 26-28, 49]. These drugs affect the tumor growth by interfering 
processes such as mitosis or DNA synthesis which are necessary for proliferation. But during 
this, the normal tissue also gets affected as the drugs cannot distinguish between the tumor cells 
and the rapidly dividing cells. This causes a lot of side effects. Paclitaxel causes side effects such 
as nausea and vomiting, loss of appetite, change in taste, thinned or brittle hair, pain in the joints 
of arms or legs, changes in the color of the nails, and tingling in the hands or toes. Doxorubicin 
also has a severe side effect, cardiotoxicity [21-23, 56] along with various side-effects such as 
acute vomiting and nausea, gastrointestinal problems, baldness, disturbances in the neurological 
system leading to hallucination and light-headedness [23].  
 
 Nanoparticles in Biosensors  1.1.3.3
  
Nanoparticles have been developed as biosensors which are used to quantify events inside the 
cells such as, release of drug from nanocarriers or interaction of biomolecules with the drug at 
the molecular level [57]. Biosensors can also be used to differentiate cancer cells from normal 
cells. Biosensors using surface resonance plasmonics have been reported to have multiple uses. 
Diverse nanostructures have been exploited for achieving optimal localized surface plasmon 
resonance (LSPR) nanosensors [58]. The exquisite sensitivity of the LSPR nanosensors to size, 
shape and environment can be harnessed to detect molecular binding events and changes in 
molecular conformation [59]. Intracellular molecular imaging using multifunctional gold 
nanoparticles which incorporate both cytosolic delivery and targeting moieties on the same 
particle is studied to utilize these intracellular sensors monitor the actin rearrangement in live 
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fibroblasts [60]. A strong molecular specific optical signal associated with effective targeting of 
actin filaments was observed (Figure 1.10). 
 
Figure 1.10 Labeled actin filaments in NIH3T3. [60] 
 
The well-studied biotin-streptavidin system was investigated by Haes et al. by exposure of 
biotin-functionalized Ag nanotriangles to 100 nM streptavidin. They observed that the LSPR 
λmax red shifted by 27 nm after the interaction of biotin on Ag nanoparticles with the streptavidin 
[61]. The use of surface plasmon resonance property of gold nanoparticles as biosensors is also 
done to recognize cancer cells from normal cells. El- Sayed et al. have used anti-EGRF 
conjugated and non-conjugated gold nanoparticles to distinguish cancer cells from normal cells 
by observing the specific and non-specific uptake in the cells. They observed that there was a 
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broadening in the red region of the SPR spectrum of non-conjugated gold nanoparticles due to 
aggregations caused by non-specific uptake. Thus observing the SPR spectra of the gold 
nanoparticles it was possible to distinguish between specific and non-specific uptake (Figure 
1.11) [62].  
 
Figure 1.11 Surface resonance plasmon of gold nanoparticles for diagnosing cancer cells by 
conjugating the gold nanoparticles with anti-EGFR.[62]  
 
Carbon nanotubes and graphene have also been studied in different fields of biosensor such as 
electrical, optical and electrochemical biosensors and have been found to be very promising 
candidates for queries such as diagnosis of life-threatening diseases to detection of biological 
agents in warfare or terrorist attacks [63]. Magnetic nanoparticles have been used for detection of 
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biomolecules and cells based on magnetic resonance effects using a general detection platform 
termed diagnostic magnetic resonance (DMR). DMR technology encompasses numerous assay 
configurations and sensing principles. To date magnetic nanoparticle biosensors have been 
designed to detect a wide range of targets including DNA/mRNA, proteins, enzymes, drugs, 
pathogens, and tumor cells. The core principle behind DMR is the use of magnetic nanoparticles 
as proximity sensors that modulate the spin-spin relaxation time of neighboring water molecules, 
which can be quantified using clinical MRI scanners or benchtop nuclear magnetic resonance 
(NMR) relaxometers [64]. Optical biosensors using fluorescence resonance energy transfer 
(FRET) for detection or sensing are getting a lot of attention these days [65]. 
. 
Figure 1.12 Detection of zinc metal ions by FRET [66] 
 
FRET has been used in carefully designed sensing systems for proteins, peptides, nucleic acids 
and small molecules [66-70]. Another example is the detection of ions in the intracellular 
environment. A FRET scheme was used to detect Zn
+
 by Hellinga et al. Figure 1.12 shows how 
the zinc sensor is based on the zinc finger (ZF) peptide. When zinc (purple) gets bound by a 
His2Cys2 primary coordination sphere in the folded ZF, the ZF undergoes a folding transition 
which can be monitored either by FRET between donor (yellow) and acceptor (red) fluorophores 
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located at the N- and C-termini of the peptide2 or by changes in the microenvironment of a 
fluorophore located in the hydrophobic core (green) [66].  
Recent advancements in the developments of luminescent quantum dots (Qdots) for FRET based 
sensing probes are highly promising in detecting molecular level changes in biological systems. 
Qdots luminescence property has also been used in sensing proteins. As seen from Figure 1.13 
Qdots which are conjugated to protein which have 5 and 11 C-terminal hystidines and the apo-
myohystidine has produced fluorescence. The protein which has 0 C- terminal does not produce 
any fluorescence, thus sensing only particular proteins [71].
 
Figure 1.13 Attachment of particular proteins to Qdots produces fluorescence of Qdots [71] 
 
Shan Huang el at. have used the Qdots fluorescence ON-OFF property to detect the ruthenium 
anticancer drug and the calf thymus DNA (ctDNA) [72]. Fluorescence of CdTe Qdots is 
quenched by ruthenium anticancer drug due to its surface binding on CdTe Qdots. The 
photoinduced electron transfer (PET) process from Qdots to ruthenium drug put the Qdots in 
OFF state. ctDNA was detected by these OFF state Qdots. As ruthenium anticancer drug broke 
away from the Qdot surfaces and were inserted into the double helix structure of ctDNA due to 
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which the PET was hindered between ruthenium drug and Qdots and the fluorescence of Qdots 
was restored (Figure 1.14). 
 
Figure 1.14 Detection of ruthenium anticancer drug and ctDNA with Qdot fluorescence ON-OFF 
process. [72] 
 
Similarly, CdSe-ZnS Qdots have been used by Medintz et al. for pH sensing in cells [73]. In this 
the Qdots were assembled with peptide-dopamine conjugates. The dopamine is in pre-reduced 
form, that is, hydroquinone form which is a poor electron acceptor. At low pH hydroquinone is 
the predominant form. Due to this low Qdot fluorescence quenching occurs. 
 
Figure 1.15 Qdot-dopamine probe for pH sensing. A) model of the probe and electron transfer 
processes which quenches the fluorescence of Qdots at high pH, B) fluorescence intensity of 
Qdots with decreasing pH. [73] 
 
 
 
A B
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As the pH is increased, due to ambient O2 in the buffer hydroquinone is oxidized to quinone 
which is a good electron acceptor. This causes higher quenching of Qdot fluorescence. Figure 
1.15 A shows the model of Qdot pH sensor and the shuttling of electrons between dopamine and 
Qdots. Figure 1.15 B shows the increase in fluorescence intensity of Qdot with decreasing pH. 
 
 1.1.4 Photodynamic Therapy for cancer treatment 
 
Photodynamic therapy (PDT) is an emerging promising treatment for cancer [74-79]. In this 
therapy a photosensitizing agent is injected into the body and is irradiated with a particular 
wavelength of light. By absorbing this light of a particular wavelength it produces a form of 
oxygen that kills nearby cells [75, 78, 79]. The wavelength used to activate the photosensitizer 
determines how far the light can travel through the body [77, 78]. Thus, to treat different areas of 
the body through PDT, specific photosensitizers and wavelengths of light are used. In addition to 
killing the cancer cells PDT can work in two more ways [75, 76, 78, 79]. It can destroy the blood 
vessels on the tumor, thus depriving the cancer tissue from getting any nourishment. Also, it can 
activate the immune system to destroy the tumor. To treat cancer inside the body through PDT 
the photosensitizer can be activated by laser which can be delivered through fiber optic cables 
(thin fibers that transmit light) [79]. For example, a fiber optic cable can be inserted through an 
endoscope (a thin, lighted tube used to look at tissues inside the body) into the lungs or 
esophagus to treat cancer in these organs. For surface tumors such as skin cancer normal light 
emitting diodes can be used [77]. 
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  Mechanism of PDT 1.1.4.1
 
The mechanism by which the harmful oxygen species are generated through PDT involves 
photoexcitation of the photosensitizer leading to the formation of triplet excited states via 
intersystem crossing from singlet excited states. These triplet states can dissipate via two types of 
photooxidative pathways. In type I photooxidation the photosensitizer transfers charge or energy 
to the ground state of molecular oxygen to give rise to the reactive superoxide radical or to the 
biomolecules and solvent molecules in the cells. In type II photooxidation the triplet state of the 
photosensitizer transfers energy to the triplet ground state of oxygen to form singlet oxygen [76, 
80-83] (Figure 1.16). These processes can occur simultaneously once the photosensitizer in 
photoactivated. The ratio between these processes depends on the type of the photosensitizer 
used, the concentrations of substrate and oxygen, and the binding affinity of the photosensitizer 
for the substrate. The half-life of singlet oxygen in biological systems is <0.04 μs, and, therefore, 
the radius of the action of singlet oxygen is <0.02 μm [80, 81, 84]. Thus the extent of cell 
damage depends on a lot of factors such as the type of photosensitizer, its extracellular and 
intracellular localization, its total dose administered, the total light dose, oxygen availability, and 
the time between the administration of the drug and light exposure. For PI1 photosensitization of 
cells in vitro, full effects are observed at about 5% O2 levels, when the oxygen is reduced to 1 %, 
the effect is also halved [81]. No photosensitization can be observed in the absence of 
measurable oxygen which was observed to be true when Gomer and Razum performed an 
experiment in which PDT was applied to induced tissue hypoxia in vivo by clamping. There was 
no PDT effect on the tissue [85].  
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Figure 1.16 Type I and Type II photooxidation pathways in PDT [83] 
 
The reactive species of oxygen formed via type I and type II processes after photoactivation of 
the photosensitizer react further in different ways to form molecules like hydroxyl radical and 
hydrogen peroxide which are highly reactive. The singlet oxygen and the oxygen species formed 
in the photochemistry of the photosensitizer are called as Reactive Oxygen Species (ROS). These 
ROS induce an oxidative stress in the cells through lipid peroxidation and the cells die. 
The superoxide radical (O2
-
) formed in the type I photooxidation can grab an electron and form 
peroxide ion (O2
2-
) which gets protonated quickly at the physiological pH to form hydrogen 
peroxide (H2O2). The overall reaction is,  
……………………………….Reaction (1) 
The superoxide also reduces Fe (III) to Fe (II). This is called as Fenton reaction 
……………………………….Reaction (2) 
 
2O2
-
   +   2H
+
             H2O2   +   O2 
O2
-
   +   Fe
3+
               Fe
2+
   +   O2 
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The hydrogen peroxide formed in reaction (1) forms hydroxyl radicals in presence of Fe (II) 
formed in reaction (2). Thus transition metal ion dependent OH
·
 formation is O2
-
 stimulated [86].  
……………………….Reaction (3) 
The hydroxyl radical ions formed in the reaction (3) abstract a proton from any biomolecule 
(lipids) and a lipid radical is formed. This lipid radical reacts with the molecular oxygen to form 
lipid peroxide which leads to a chain reaction of lipid peroxidation. 
…………………………..Reaction (4) 
Another way of lipid peroxidation is reaction between the singlet oxygen formed in the type II 
photooxidation and the lipid molecules. This reaction cannot be considered as the initiation of 
the lipid peroxidation chain reaction, because the singlet oxygen does not abstract a proton to 
give rise to a radical. It directly reacts with lipid molecules to form lipid peroxide [86].  
………………………………………Reaction (5) 
 
  Small molecules for PDT 1.1.4.2
 
Different kinds of photosensitizers are used in PDT. Few of the photosensitizer examples are 1) 
pthalocyanines, 2) chlorines such as mTHPC (meta tetrahydroxyphenyl chlorin), 3) porphyrines 
such as BPD (benzoporphyrine derivative), HP (hematoporphyrin), HPD (hematoporphyrin 
derivative), 4) azulene, 5) erythrosine, 6) 5-ALA (5-aminolevulinic acid). Porphyrines are the 
most studied photosensitizers to date. They have a general structure of four pyrrole rings 
Fe
2+
   + H2O2              Fe
3+
   +  OH
·
  +  OH
-
 
OH
·
   +   L-H                  L
·
   +   H2O 
L
·
   +   O2                  LOO
· 
LOO
·
   + L-H                LOOH   +   L
·
 
1
O2   +   L-H               LOOH 
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connected with methylene bridges in a cyclic fashion and a metallic side chain. HPD, tin ethyl 
etiopurpurin (Purlytin) and motexafin lutetium were used as photosensitizers to treat breast 
cancer in patients [87-89]. Gynecological cancers have also been treated with different 
photosensitizers such as 5-aminolevulinic acid, HPD using PDT [90-92]. Patients with 
gastrointestinal tumors were treated with three photosensitizers – ALA, photofrin and mTHPC 
and red light using light dose depending on the photosensitizer (10-15 J/cm
2
 for mTHPC and 50-
150 J/cm
2
 for ALA and photofrin) [93]. Intraperitoneal malignancies in patients were treated 
with dihematoporphyrin ethers (DHE) and irradiated with green light for PDT [94]. All these 
photosensitizers were administered into the patient bodies either by intravenous or orally and 
then light was irradiated on the tumor area. Patients with pancreatic cancer were treated with 
mTHPC and light was delivered using fibers to induce necrosis in the malignant tissue [95].  
These photosensitizers are directly absorbed in the cancer cells. 
 
  Nanoparticles for PDT 1.1.4.3
 
Most of the photosensitizers are hydrophobic and pose problems such as prolonged cutaneous 
photosensitivity and selectivity. These problems can be overcome by incorporating the 
photosensitizer in the nanoparticles. This can be done by enveloping the photosensitizer inside 
the nanoparticles wherever necessary and by reducing the hydrophobicity by attaching the 
photosensitizer to a hydrophilic nanoparticle. The incorporation of photosensitizer in 
nanoparticles can be achieved in two ways: 1) conjugation of the photosensitizer to the NPs, and 
2) encapsulation of the photosensitizer inside the NPs. Examples of NPs which carry 
photosensitizers are organic NPs, inorganic NPs, polymeric NPs, micelles, liposomes. In the 
inorganic type NPs silica coated gold NPs were found to be very efficient in delivering chlorin 
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e6 (Ce6) photosensitizers in MDA-MB-435 cells. These AuNCs@SiO2-Ce6 NPs showed an 
improved PDT efficacy as compared to free Ce6 as shown in Figure 1.17 [96]. 
 
Figure 1.17 A) fluorescence of free Ce6 and Ce6 conjugated with gold NPs (AuNCs@SiO2.Ce6) 
in MDA-MB-435 cells showing that the Ce6 photosensitizer is efficiently delivered in cells when 
conjugated with NPs as compared to free Ce6, B) cell viability of MDA-MB-435 administered 
with free Ce6 AuNCs@SiO2.Ce6, with and without light.[96] 
 
Similar observation was done by Ito et al. when 5-ALA and 5-ALA-Me was incubated with 
MCF-7 and HepG2 cell lines in presence and absence of citrate capped gold NPs (AuNPs). They 
found that the cell damage was a factor of 1.5 more in presence of AuNPs as compared to 5-
ALA alone [97]. Mannose functionalized silica coated magnetic nanoparticles encapsulating 
porphyrin photosensitizer were used by Perrier et al. for PDT [98], while photosensitizer tetra-
substituted carboxyl aluminum phthalocyanine (AlC4Pc) covalently linked to the mesoporous 
silica shell and superparamagnetic nanoparticles at the core were studied by Wang et al. [99]. 
Silica nanoparticles encapsulating the photosensitizing drug 2-devinyl-2-(1-
hexyloxyethyl)pyropheophorbide (HPPH) were used in PDT to kill HeLa cells [100]. In another 
example of silica NPs a third-generation (G3) polyamidoamine (PAMAM) was grafted to the 
surface of porous hollow silica nanoparticles followed by the attachment of gluconic acid (GA) 
for surface charge tuning. The PAMAM-functionalized outer layer with a large number of amino 
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groups allowed high loading efficacy of the photosensitizer aluminum phthalocyanine 
tetrasulfonate (AlPcS4). These silica NPs conjugated with the photosensitizer were studied in 
MCF-7 cell lines and were observed to have higher efficiencies in killing the cells through PDT 
as compared to free photosensitizer as shown in Figure 1.18 [101]. 
  
Figure 1.18 Cell viability of MCF-7 with free AlPcS4 and silica NPs conjugated with AlPcS4 
showing that the efficacy of PDT was increased due to better delivery of the photosensitizer 
through silica NPs in cells [101] 
 
Photosensitizer AlC4Pc was covalently conjugated to a mesoporous silica network to deliver the 
photosensitizer in HeLa cells [102]. Organically modified silica nanoparticles encapsulating the 
hydrophobic photosensitizer HPPH for PDT were also developed by Ohulchanskky [103] 
(Figure 1.19). Polymeric NPs like Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl 
methacrylate-co-p-nitrophenylcarbonyloxyethyl methacrylate] (PMBN) doped with vertiporfin 
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as the photosensitizer to study PDT in A431 cells [104] and polymeric micelles of block 
copolymer poly(ethylene glycol)–co-poly(D,L-lactic acid) (PEG-PLA) loaded with 5,10,15,20-
tetrakis(mesohydroxyphenyl)porphyrin (mTHPP) as the photosensitizer have been reported 
[105]. Liposomes doped with various photosensitizers have been studied for application in PDT 
[106]. Phthalocyanine conjugated polypropylenimine dendrimers, and porphyrine 
phthalocyanine decorated dendrimers [107, 108] have also been reported. 
 
Figure 1.19 Encapsulation of photosensitizer in organically modified silica nanoparticles for 
effective delivery of the sensitizer [103] 
 
Recently, photosensitizer-doped conducting polymer nanoparticles have received attention as 
potential photosensitizers for PDT. Photosensitizer tetra-phenylporphyrine (TPP) doped 
conjugated polymer poly(9,9-dihexylfluorene) PDHF nanoparticles were developed and 
characterized by Grimland et al. [109]. The polymer has a high two photon cross section which 
makes it a promising candidate for near infrared multiphoton photodynamic therapy. In this the 
nanoparticles absorb light and transfer energy efficiently to the TPP photosensitizer producing 
high amounts of singlet oxygen (Figure 1.20). The formation of singlet oxygen was proved by 
UV-vis spectroscopy.  
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Figure 1.20 Energy transfer process in conjugated polymer PDHF doped with TPP 
photosensitizer and the absorbance and emission spectra of the undoped and doped conjugated 
polymer nanoparticles. The blue spectrum is the emission of undoped PDHF polymer while the 
red spectrum is the emission of the doped PDHF nanoparticles. The emission of the polymer is 
reduced to background due to energy transfer to TPP. [109] 
 
DNA damage as a proof-of-concept for formation of singlet oxygen was shown by these authors 
(Figure 1.21) [109]. 
 
Figure 1.21 Electrophoresis gel image showing DNA damage by NPs-generated ROS. Lane 1: 1 
kb Mw ladder, lanes 2–4: plasmid DNA; DNA + H2O2 (50 mM); DNA + Fe2+ (2 mM) + H2O2. 
Lanes 5–8:DNA + nanoparticles irradiated for 0, 50, 100 and 200 min, respectively. [109] 
 
Shen et al. concurrently encapsulated TPP in conjugated polymer, poly[9,9-
dibromohexylfluorene-2,7-ylenethylene-alt-1,4-(2,5-dimethoxy) phenylene] (PFEMO) and 
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proved the formation of singlet oxygen by singlet oxygen luminescence [110]. The two-photon 
excitation properties of TPP were enhanced by the PFEMO  
There are examples in which NPs are developed in such a way that they themselves act as a 
photosensitizer when photoirradiated inside the cells. The inorganic type of such NPs includes 
quantum dots [111, 112], gold nanorods (Au NRs) [113]. Nano titanium oxide nanoparticles 
were used to see the effect of PDT on human keratinocyte HaCaT cells and it was observed that 
the cell viability reduced with increase in dose of NPs [114]. 
A lot of work has been done on targeting cancer cells with different ligands to make PDT more 
specific, that is, solving the problem of selectivity for photosensitizers so as to reduce the side 
effects by avoiding the uptake of photosensitizers in normal cells (Figure 1.22). 
 
Figure 1.22 Folate receptors mediated uptake of nanoparticles conjugated with folic acid. 
 
Recently PDT using Fe3O4/Au NPs attached with 5,10,15,20-tetrakis(4-hydroxyphenyl)-
21H,23H-porphine (tHPP) as a photosensitizer and affibody for Her-2 specificity to target SK-
OV-3 cells was studied [115]. These NPs were tested in xenografted tumor also and were found 
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to be very effective in showing specificity and inhibiting the growth of the tumor as compared to 
the NPs which were not attached with the affibody peptide. EGFR targeted PDT using liposomes 
attached with cetuximab as the targeting antibody and BPD as photosensitizer in ovarian cancer 
cells gave very promising results [116]. Conjugation of folic acid for selective delivery of 
photosensitizer in different types of cancer tissues is also well documented and is still in 
progress. Polymeric micelles conjugated with folic acid to deliver meta - tetra 
(hydroxyphenyl)chlorin (mTHPC) in xenografted KB cells in vitro and in vivo is studied by Syu 
et al.[117]. CdTe quantum dots acting as a photosensitizer and conjugated with folic acid for 
specificity were studied by Morosini et al. in KB cells as folate receptor (FR) overexpressing 
cells [118]. Zinc tetraaminophthalocyanine (ZnaPc) with high cross section for two-photon 
excitation conjugated with folic acid to observe the selective delivery of the photosensitizer to 
FR positive KB cells and FR negative A549 cells showed that the ZnaPc-FA is a promising 
candidate for PDT [119]. Graphene oxide nanoparticles loaded with photosensitizer chlorin e6 
(Ce6) and conjugated with folic acid were used in PDT to see the effect on MGC803 cells [120]. 
These nanocarriers were showed to have great potential as efficient drugs in PDT.  
 
  Significance of Research 1.2
 
Efficient and effective treatment involves the drug or the photosensitizer to be delivered in 
correct amounts, at correct sites of malignancy without causing any side effects. Such a treatment 
can be achieved by using hydrophilic drugs and sensitizers, which can stay in the blood 
circulation for longer time, and are efficiently and selectively uptaken by cancer cells while 
avoiding normal cells. Unfortunately, drugs and photosensitizers are usually hydrophobic and 
non-selective between normal and cancer cells. Treatment is often less efficient and causes a lot 
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of side effects by affecting the healthy tissue due to these issues. In addition, patients that 
underwent PDT show prolonged cutaneous photosensitivity, which is an unresolved issue with 
PDT.  
 
 1.2.1  Conjugated polymer and fullerene doped/blended conjugated polymer nanoparticles 
 
1 Hydrophilic drugs usually remain in circulation until excreted, while being uptaken slowly by 
cells. However, most pharmaceuticals for cancer treatment are hydrophobic, which causes poor 
circulation in the blood stream and ineffective delivery. Hydrophobic compounds tend to leak 
out of the porous tumor vasculature and are retained in tumor tissue, where aggregation takes 
place [121, 122]. Under these circumstances the uptake of drug by tumor cells is severely 
limited. The hydrophobicity issue is addressed here for PDT photosensitizers by fabricating 
nanoparticles out of conjugated polymers. This approach was motivated by the hypothesis that 
conjugated polymers themselves can act as photosensitizers, without the need to blend or 
functionalize with common small molecule photosensitizers. As the conjugated polymer itself is 
hydrophobic, during the fabrication of nanoparticles by the reprecipitation method the polymer 
aggregates away from water to form nanoparticles. These nanoparticles are water dispersible and 
the solution is a suspension of nanoparticles in water (like oil in water emulsion). It is stable in 
cell culture media. Thus the controlled aggregation of the conjugated polymer by preparing 
nanoparticles out of it makes the polymer accessible in the cells without aggregating further in 
the tumor tissue.  
2. The circulation time in blood is improved and made longer by blending the conjugated 
polymer with a comb-like amphiphilic polymer PS-PEG-COOH (Polystyrene Graft Ethylene 
Oxide with carboxylic acid) having hydrophobic backbone made of polystyrene and poly-
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ethylene glycol (PEG) side chains terminating in carboxylic acid groups. PEG has been shown to 
increase circulation time in the blood stream [123, 124]. The nanoparticles fabricated out of this 
blend have a core of hydrophobic conjugated polymer mixed with polystyrene backbone. The 
PEG side chains with the carboxylic acid groups point towards water due to their hydrophilicity. 
This further increases the water dispersibility of the conjugated polymer and increases the blood 
circulation time.  
3. Theoretically, significant drug concentrations in diseased compartments of the body should be 
achieved without distributing the drug throughout healthy tissue. In practice, due to limited 
circulation times, drug hydrophobicity and lack of selectivity to disease targets, only limited 
amounts of drug reach the intended site. Because of this, larger amounts of drugs than necessary 
must be applied, which causes the healthy tissue to get affected by the adverse effects of the 
cytotoxic drugs. Many promising pharmaceuticals have failed clinical trials due to these issues. 
Strategies to efficiently and selectively deliver photosensitizer and drugs to target sites have 
therefore received tremendous attention in the field with the aim to overcome these issues and 
reduce cytotoxicity related side effects [121, 122]. This is achieved here by conjugating the 
polymer nanoparticles with ligands which can bind to specific receptors overexpressed on the 
cell surface of cancer cells. Cancer cells overexpress receptors such as folate receptors (FR), 
epidermal growth factor receptors (EGFR), Her-2 receptors and others depending on the type of 
cancer. Ligands specific towards these receptors such as folic acid (FA), antibodies Erbitux or 
Cetuximab and affibody respectively can be used to target particular types of cancer. Here folic 
acid has been used to functionalize the nanoparticles and target them towards the cell lines which 
overexpress folate receptors on their surfaces. The carboxylic acid groups from PS-PEG-COOH, 
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which are protruding out on the surface of the nanoparticles were modified to conjugate folic 
acid through the traditional EDC chemistry.  
4. After delivering the drug or photosensitizer in the cells it is necessary to have the knowledge 
of its course of action in the cells. To have a safer and efficient treatment the measurements on 
events such as amount of drug released from the nanocarriers in the cells, amount of drug getting 
used up in the cells, time needed to release the drug in the cells are essential. Specifically, 
knowledge on the localization of photosensitizer for PDT in tissue is necessary to evaluate 
potential effectiveness of PDT treatment and dispersion of the photosensitizer throughout healthy 
and diseased tissue. The latter is important for unresolved issues with PDT such as prolonged 
cutaneous photosensitivity. As the conjugated nanoparticles are highly fluorescent, they can be 
easily tracked at the particle level and their localization in the cells, whether those are in 
endosomes, lysosomes or in cytoplasm can be known.   
5. Along with hydrophobicity and non-selectivity, photosensitizers like vertiporfin, 5-
aminolevulinic acid, methyl 5-aminolevulinic acid and photofrin have substantial problems with 
prolonged cutaneous photosensitivity of patients [125, 126]. Cutaneous photosensitivity causes 
skin diseases showing symptoms such as pigmentation and phototoxic reactions including itchy 
or burning sensation, erythema and swelling. Cutaneous photosensitivity can be avoided by 
encapsulating the photosensitizer drugs into nanocarriers that can carry the drug to the required 
tumor tissue. Only when the photosensitizer is released from the nanocarrier in the intracellular 
environment ROS will be formed. As the conjugated polymer itself acts as a photosensitizer 
here, the use of any additional photosensitizer is not needed for the PDT, which in turn avoids 
the possibility of photosensitivity caused by these photosensitizers. However, at this time it is not 
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known if prolonged cutaneous photosensitivity could be caused by the conjugated polymer 
nanoparticles.  
 
 1.2.2 Quantum dot biosensors for drug delivery, quantification and drug discovery 
 
A lot of work has been reported on delivering drugs in cells via nanocarriers such as inorganic 
nanoparticles, polymeric nanoparticles, liposomes, and dendrimers. But little is known about the 
delivery and release events of a drug from the nanocarriers in the cells. Whether or not the 
nanocarriers with drug actually entered the cell, the location of drug release in the cell, the time 
required for drug release and the amount of drug released are questions that have often remained 
unanswered. These are important questions that need to be addressed in order to develop 
effective, safe and efficient drugs. A biosensor that can selectively and effectively carry drug to 
the target site, report on the event of drug release inside the cells, can provide the location of 
drug release, and can quantify the amount of drug released is needed. Such a biosensor would not 
only provide a way to improve treatment efficiency, but would also bring a paradigm shift in the 
field of drug discovery.   
Here a biosensing probe was developed for which the core functionality consists of fluorescence 
quenching and restoration of Qdots upon conjugation and release of a ligand, respectively. Drug 
was attached to the ligand for delivery by the Qdots biosensor. A biocompatible polymer shell 
was decorated with targeting ligand for selective delivery, PEG for improved water dispersion 
and circulation time in the blood stream, and a fluorescent dye for ratiometric quantification of 
the amount of drug that is delivered 
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The ligand used here is dopamine, which was conjugated to CdS:Mn/ZnS Qdots through a zero 
length linker molecule such as carbon disulphide (CS2). Upon conjugation, the fluorescence of 
Qdots is quenched (OFF probe) due to charge transfer between dopamine and Qdots. The 
transfer of electrons occurs to or from Qdots depending on the oxidation state of dopamine When 
the OFF probe enters the cytosolic environment in the cells, the glutathione present in the 
cytoplasm displaces the CS2-dopamine(-drug) conjugates from the Qdots surfaces and 
fluorescence is restored (ON probe). Therapeutic drug (STAT3 inhibitor) is attached to the 
dopamine ligand and is thus released from the probe upon delivery in the intracellular 
environment and the fluorescence of the Qdots is restored. The quantification of release of drug 
in the cells is achieved by ratiometric measurement on the fluorescence of Qdots (variable by 
amount of ligand released) in the ON state with respect to the constant emission of dye in the 
chitosan shell. By measuring the ratio of the dye fluorescence which stays constant to the 
fluorescence of Qdot (which depends on the release of the drug), the amount of drug released in 
the cells can be calculated.  
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 INSTRUMENTATION AND EXPERIMENTALS CHAPTER 2
 
 Introduction 2.1
 
To make the drugs used in therapeutics for cancer more effective towards curing the cancer, it is 
necessary to understand how they work in body. To understand this it is essential to learn their 
properties and mechanism of action in-vitro before introducing them in-vivo. This was achieved 
by growing cell lines in lab and performing experiments on them for in-vitro studies. Conjugated 
polymer nanoparticles were fabricated and characterized to study their applications as the next 
generation photosensitizers in photodynamic therapy. Functionalization of nanoparticles with 
folic acid as targeting agent towards folate receptor expressing cell lines was achieved to make 
PDT targeted thus reducing the side effects by avoiding uptake in healthy cells. The cell 
viabilities after PDT were quantified by MTT and MTS assays and were confirmed by flow 
cytometry experiments which are discussed in detail here within. Fluorescence microscopy 
including confocal and epiluminescence were used for imaging purposes. Single Particle 
Spectroscopy (SPS) was performed to confirm the uptake and stability of nanoparticles in cells. 
In the case of Qdot-dopamine biosensor probe the restoration of Qdot fluorescence was 
confirmed by SPS and confocal microscopy. All the experimental details have been discussed in 
the following subsections.  
 Nanoparticle fabrication 2.2
 
 2.2.1 Doped NPs and CPNPs fabrication 
 
Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV) with molecular 
weight 150,000-250,000 g/mol (average Mn, PDI- 2.2) was purchased from Sigma Aldrich and 
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used without any further purification. Phenyl-C61-butyric acid methyl ester (PCBM) was 
purchased from Sigma-Aldrich and was used as is. THF (tetrahydofuran, Drisolv) was purchased 
from EMD. The nanoparticles were fabricated following our previously published protocol. [127, 
128]. In short, for CPNPs 1 mg MEH-PPV was dissolved in THF and was diluted to a 10
-6
 M 
concentration by using absorbance and Lambert-Beer law. 1ml of this solution of MEH-PPV in 
THF was quickly injected into 4 ml of DI water under vigorous stirring. Stirring was stopped 
immediately after injection of the polymer solution in water. While for doped NPs a blended 
solution containing a 1:1 mass ratio of the conjugated polymer MEH-PPV and the fullerene 
PCBM was prepared in THF and diluted further to get 10
-6
 M concentration of MEH-PPV. 1 ml 
of this solution was quickly injected in 4 ml water. Due to hydrophobicity the polymer and 
fullerene aggregated away from water to form nanoparticles. The structures of MEH-PPV and 
PCBM and the reprecipitation method of fabrication of nanoparticles are shown in Figure 2.1A 
and B.  
 
Figure 2.1 A) chemical structures of MEH-PPV and PCBM, B) reprecipitation method of 
nanoparticle fabrication. The stirring was done at 1200 rpm. As soon as the injection was 
completed the stirring was stopped immediately.  
 
 
 
 
A B
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 2.2.2 FNPs fabrication 
 
  Preparation of MPNPs  2.2.2.1
 
Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV) with molecular 
weight 150,000-250,000 g/mol (average Mn, PDI-2.2) was purchased from Sigma Aldrich and  
was purified to remove the low molecular weight polymer chains. Comb-like polymer 
Polystyrene Graft Ethylene Oxide with carboxylic acid (PS-PEG-COOH) with molecular weight  
36500 g/mol (average Mn, PDI-1.3) was purchased from Polymer Source Inc and used as is. 
THF (tetrahydofuran, Drisolv) was purchased from EMD. 
2.2.2.1.1 Purification of MEH-PPV 
 
For purification 6 ml of HPLC grade acetone (Sigma Aldrich) was added to 3 mg MEH-PPV in a 
vial. The vial was heated gently at a low temperature on a hot plate to obtain yellow supernatant, 
which was removed using a glass pipette without removing the MEH-PPV at the bottom of the 
vial. A small amount of chloroform (approximately 3 ml) (Sigma Aldrich) was added to this vial 
to dissolve MEH-PPV. In this orange solution acetone was added in 1:5 ratio of 
chloroform:acetone. This suspension was transferred to a centrifuge tube and centrifuged for 10 
minutes at 4000 rpm. The high molecular weight MEH-PPV settles at the bottom while the low 
molecular weight MEH-PPV remains in the supernatant. The supernatant was removed and the 
procedure was repeated until the supernatant turn light pink colored (4 repetitions were needed). 
The purified MEH-PPV was covered with a parafilm, small holes were punctured in it and dried 
overnight. 
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2.2.2.1.2 Fabrication of MPNPs 
 
1mg purified MEH-PPV was dissolved in 3ml THF to obtain 0.33 mg/ml stock solution of MEH-
PPV and 1mg PS-PEG-COOH was dissolved in 50 ml THF to obtain 0.02 mg/ml stock solution 
of PS-PEG-COOH separately. To obtain 2:1 molar ratio 1 ml of MEH-PPV stock solution was 
mixed with 1ml PS-PEG-COOH stock solution and was diluted further with THF to 10
-6
 M 
concentration of MEH-PPV. 1 ml of this diluted solution was quickly injected into 4ml of DI 
water under vigorous stirring. Stirring was stopped immediately after injection of solution into 
water. Due to hydrophobicity the MEH-PPV and PS backbone of the non-fluorescent polymer 
self-aggregate to form nanoparticles. The hydrophilic PEG and COOH parts of the polymer 
extend towards water, now available for further functionalization by folic acid. The solution 
obtained is a suspension of MPNPs (MEH-PPV—PS-PEG-COOH blended Nanoparticles) in 
water and was used for functionalization with folic acid. 
 Functionalization by EDC chemistry 2.2.2.2
 
For functionalization the carboxylic groups on the MPNPs surfaces were activated by N-
Hydroxysuccinimide (NHS) and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) purchased from Sigma Aldrich. Excess NHS was added to 15 ml MPNPs 
suspension in water. After 15 minutes of stirring excess EDC was added to this solution. The 
solution of MPNPs, NHS and EDC was stirred again for 15 minutes. 1:1 molar ratio of PS-PEG-
COOH:folic acid (Sigma Aldrich) was used for the final functionalization step and stirred for 2 
hours. The solution obtained is unfiltered folic acid functionalized nanoparticles (FNPs). 
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 Centrifugal filtration 2.2.2.3
 
15 ml of FNPs were filtered by centrifugal filtration to remove the unreacted folic acid, NHS and 
EDC from the nanoparticle solution. Amicon Ultra-15 Centrigugal Filter Devices with Molecular 
Weight Cutoff 10,000.was used for filtration. The solution was spun at 4000 x g in swinging 
bucket rotor for 60 minutes. To remove the unreacted NHS, EDC and folic acid from the FNPs 
solution, 6 to 7 filtrations were needed. After each filtration cycle approximately 3ml of filtrate 
was removed. After each filtration the volume of the FNPs solution was adjusted back to 15 ml 
by adding DI water, effectively replacing the unreacted folic acid, NHS and EDC from the 
solution with DI water. Progress was monitored by Uv-vis and fluorescence spectroscopy 
completed for each filtrate as shown in Figure 2.2A and B 
 
Figure 2.2 Centrifugal filtration for washing functionalized nanoparticles tracked by A) UV-vis 
and B) fluorescence spectroscopy. All the unreacted folic acid, NHS and EDC were removed 
from the FNPs suspension during 6
th
 or 7
th
 filtration as seen from fluorescence spectra of folic 
acid after which there is no change in the intensity of folic acid emission. Excitation wavelength 
is 350 nm. 
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 Characterization of nanoparticles 2.3
 
 2.3.1 DLS, TEM, AFM for size determination 
 
 Dynamic light scattering (DLS) 2.3.1.1
 
The size of the nanoparticles was determined with a Precision Detector Dymanic Light 
Scattering (PD2000DLS) machine. Data was analyzed using the Precision Deconvolve software. 
For doped NPs and CPNPs the nanoparticle suspension was diluted by adding 50 µl of 
nanoparticle suspension into 3 ml of DI water in a quartz cuvette of 1 cm path length. For FNPs 
size of nanoparticles was measured the same way after each centrifugal filtration.   
 Transmission electron microscopy (TEM) 2.3.1.2
 
The diameter of the doped NPs and CPNPs was determined using transmission electron 
microscopy (TEM, Phillips Tecnai F 30). A drop of the nanoparticle suspension was placed on a 
TEM grid and vacuum dried before imaging. 
 Atomic force microscopy (AFM) 2.3.1.3
 
Atomic Force Microscopy was run on a Digital Instruments Multimode and Dimension 3100 
system with NanoScope IIIa controller. After dilution the same way for DLS, 6 µl of MPNPs, 
CPNPs and FNPs suspensions in water were dropped onto freshly peeled mica substrates. These 
samples were vacuum dried for 15 min before imaging. 
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 2.3.2 UV-vis and fluorescence spectroscopy for optical properties 
 
 UV-vis spectroscopy 2.3.2.1
 
The absorption spectroscopy on the nanoparticles suspension in water was completed in a 1 cm 
path length quartz cuvette after diluting the suspensions as explained in the DLS section, with an 
Agilent 8453 spectrophotometer using the Chemstation software. 
 Fluorescence spectroscopy 2.3.2.2
 
The fluorescence spectroscopy on the nanoparticles suspension in water was performed in a 1 cm 
path length quartz cuvette after dilution of the suspensions as described in DLS section, with a 
Nanolog
TM
 HoribaJobin Yvon fluorimeter. 
 2.3.3 FTIR for FNPs  
 
Fourier Transformation Infrared Spectroscopy (FTIR) analysis of FNPs was completed using a 
Perkin Elmer Spectrum 100 Series (650-4500 cm-
1
) FTIR Spectrophotometer. 30 ml filtered 
FNPs, MPNPs and CPNPs were frozen in DI water and then lyophilized (FreeZone 4.5L Freeze 
Dry System, Labconco) to obtain a powder and FTIR was run on these samples. CPNPs and 
MPNPs were run as control experiments. 
 
 Cell culture 2.4
 
All the experiments related to cell culture and in-vitro studies are explained in this section and 
subsections. Mostly, incubation of cell lines with different nanoparticles, counting the cells for 
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cell viability assays and flow cytometry is explained. Staining the cells with different dyes for 
fluorescence imaging and flow cytometry is covered. 
 2.4.1 Propagation (maintaining the cell culture)  
 
TE 71 (Mouse thymic epithelial normal cell line) , MDA-MB-231 (Human breast cancer cell 
line), MIA PaCa2 (Human pancreatic cancer cell line), A549 (Human lung cancer cell line) and 
OVCAR3 (Human ovarian tumor cell line) cell lines were purchased from ATCC and grown in 
10 % Fetal bovine serum (FBS) in Dulbecco's Modified Eagle Medium (DMEM), under 5 % 
CO2 and humid atmosphere at 37
0
C. Cells were harvested using 0.05 % trypsin in Dulbecco's 
Phosphate-Buffered Saline (DPBS) 
 2.4.2 Nanoparticle uptake studies 
 
For studying the uptake of doped NPs, FNPs and Qdot probes various cell lines were grown upto 
40% confluency in 35 mm petri dishes in complete growth medium for 24 hours. For CPNPs the 
cells were counted by using hemocytometer and 10,000 cells were added in each well in 96 well 
plate and kept in the incubator for 24 hours. 
For doped NPs, after growing for 24 hours, TE 71, MDA-MB-231, A549 and OVCAR3 cells 
lines were washed with DPBS and incubated with 2 x 10
-4
 mg/ml doped NPs in DMEM for 24 
hours. Then the cells were washed with DPBS for 2-3 times and were fixed with 4 % 
paraformaldehyde. After fixing the cells were stained with DAPI nuclear dye. The cells were 
suspended in DPBS for imaging. 
For CPNPs, increasing concentrations of CPNPs in DMEM (0.4 x 10
-4
 mg/ml, 2 x 10
-4
 mg/ml 
and 3.6 x 10
-4
 mg/ml) were added to TE 71, MDA-MB-231, A549, and OVCAR3 cells lines in 
43 
 
the 96 well plate and incubated for 24 hours. Then the cells were washed with DPBS 2-3 times 
and harvested with 0.05 % trypsin. All the cells lines with different concentrations of CPNPs 
were added in different petri dishes and incubated for another 24 hours in complete media. Then 
the cells were washed for 2-3 times with DPBS and fixed with 4 % paraformaldehyde. After 
fixing the cells were stained with DAPI nuclear dye. The cells were suspended in DPBS for 
imaging. 
For FNPs, TE 71, MIA PaCa2, A549, and OVCAR3 cells lines were incubated with 2 x 10
-4
 
mg/ml FNPs in complete media for 24 hours. Then the cells were washed for 2-3 times with 
DPBS and fixed with 4 % paraformaldehyde. After fixing the cells were stained with DAPI 
nuclear dye. The cells were suspended in DPBS for imaging. 
For Qdot probe, TE 71, A549 and OVCAR3 cell lines were incubated with 0.05 mg/ml Qdot 
probe in DMEM for 24 hours. Then the cells were washed for 2-3 times with DPBS and fixed 
with 4 % paraformaldehyde. The cells were suspended in DPBS for imaging. 
 2.4.3 MTT and MTS viability assays 
 
For doped NPs and CPNPs MTT viability assay was used to evaluate the intrinsic cytotoxicity of 
the nanoparticles and the effect of PDT in different cell lines. For FNPs MTS viability assay was 
used for the same reasons. There are only two differences between MTT and MTS assays. For 
MTT the formazan which is formed in the form of crystals needs to be dissolved by using 
solubilization solution or acidified isopropanol, while in MTS there is no need of the additional 
step of solubilization of formazan. Also, in MTT the absorbance is read at 570 nm while in MTS 
the absorbance is read at 490 nm. 
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 Intrinsic cytotoxicity 2.4.3.1
 
For doped NPs and CPNPs, TE 71, MDA-MB-231, A549, and OVCAR3 cell lines were grown 
in 96 well plates at a density 10,000 cells/well for 24 hours. Then the cells were incubated with 
0.4x10
-4
 mg/ml, 2x10
-4
 mg/ml and 3.6x 10
-4
 mg/ml doses of respective nanoparticles in DMEM, 
together with the corresponding controls (0 mg/ml and with complete media) for up to 24 hours. 
Cell viability was determined 0, 24, 48, 72 and 96 hours after addition of nanoparticles by MTT 
assay. For the 0 and 24 hour time point, MTT was added immediately after adding nanoparticles 
and 24 hours after addition of nanoparticles, respectively. For the 48, 72 and 96 hours readings, 
the nanoparticle solution was removed after 24 hours and replaced with the complete media. 
MTT was then added at the corresponding time points. MTT was allowed to incubate for 4 hours 
to allow formazan to form. Then the solubilization solution was added and after 6 hours the 96 
well plates were read. The readings were aquired at 570nm on a Biotek ELx800 absorbance 
microplate reader. 
For FNPs, TE 71, MIA PaCa2, A549, and OVCAR3 cell lines were grown in 96 well plates at a 
density 10,000 cells/well for 24 hours. Then the cells were incubated with 0.4x10
-4
 mg/ml, 2x10
-
4
 mg/ml and 3.6x 10
-4
 mg/ml doses of FNPs in complete media together with the corresponding 
controls for up to 24 hours. Cell viability was determined 0, 24, 48, 72 and 96 hours after 
addition of FNPs by MTS assay. For the 0 and 24 hour time point, MTS was added immediately 
after adding FNPs and 24 hours after addition of FNPs, respectively. For the 48, 72 and 96 hours 
readings, the FNPs solution was removed after 24 hours and replaced with the complete media. 
MTS was then added at the corresponding time points. MTS was allowed to incubate for 4 hours 
to allow formazan to form. The readings were acquired at 490 nm on a Biotek ELx800 
absorbance microplate reader. 
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 PDT 2.4.3.2
 
Three light doses (60 J/cm
2
, 120 J/cm
2
 and 180 J/cm
2
) and three nanoparticles doses (0.4x10
-4
 
mg/ml, 2x10
-4
 mg/ml and 3.6x 10
-4
 mg/ml) along with one control dose (0 mg/ml) were used for 
PDT. For each light dose four post-PDT incubation periods (0 hours, 2 hours, 4 hours and 12 
hours) were evaluated. Cells were grown in 96-well plates for 24 hours. Then the cells were 
incubated with different doses of doped NPs, CPNPs and FNPs. After 24 hours the media was 
replaced with HBSS (Hank's Balanced Salt Solution) and the 96-well plates with the cells were 
exposed to visible light by using a solar simulator (Newport 67005 Oriel Instruments) and a UV 
filter (FSQ-GG400) to block the UV light. Then MTT or MTS was added to the 96-well plates 
immediately after PDT (0 hours), and 2, 4 and 12 hours post-PDT incubation. The experiment 
was performed 3 times (n=3). The reading was done as above (Intrinsic cytotoxicity) 
 
 2.4.4 Detection of ROS after PDT 
 
For doped NPs and CPNPs A549 and OVCAR3 cell lines were grown in 35 mm petri dishes. 2 
x10
-4
 mg/ml nanoparticles in DMEM were incubated with the cell lines for 24 hours. Then the 
cells were washed with DPBS and were suspended in HBSS. The samples were treated with a 
180 J/cm
2
 light dose. CellROX Green Reagent (Invitrogen) was added to the media (1) 
immediately after the light treatment (0 hours) and (2) after 2 hours of post treatment incubation. 
After 30 min the remaining reagent was washed away, cells were fixed with 4% 
paraformaldehyde, and stained with DAPI. The cells were kept in DPBS for imaging. Three 
negative controls (1) no nanoparticles and no light dose (i.e. untreated cells), (2) treatment with a 
light dose of 180 J/cm
2
 in the absence of nanoparticles, and (3) cells incubated with nanoparticle 
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dose of 2×10
−4
 mg/ml kept in the dark, were studied. The positive control was performed by 
incubating the cells with 100 μM H2O2. For FNPs the same procedure was done by using TE 71, 
MIA PaCa2, A549, and OVCAR3 cell lines and by incubating the cell lines with 2 x 10
-4
 mg/ml 
FNPs in complete media. 
 2.4.5 Detection of apoptosis and necrosis by imaging 
 
TE 71, MDA-MB-231, A549 and OVCAR3 cell lines were administered with 2 x 10
-4
 mg/ml 
doped NPs and were exposed to the doses of light (60 J/cm
2
, 120 J/cm
2
 and 180 J/cm
2
). The cells 
were stained with PI and annexin V FITC along with DAPI. imaging was done on these samples. 
 2.4.6 Endosome and lysosome tracking 
 
OVCAR3 cell line was grown in 35 mm petri dishes. 2 x 10
-4
 mg/ml FNPs in complete media 
was incubated with the cells. After 24 hours cells were washed with DPBS and again complete 
media was added with endosome or lysosome dye. After 30 minutes the cells were washed and 
stained with DAPI. The cells were suspended in HBSS for live imaging.  
 2.4.7 Flow cytometry 
 
 Quantification of uptake of nanoparticles 2.4.7.1
 
The experiment was performed for doped NPs, CPNPs and FNPs. For doped NPs and CPNPs 1 x 
10
6
 cells/ml concentration solutions of TE-71, MDA-MB-231, A549 and OVCAR3 cell lines 
were incubated with 2x10
-4
 mg/ml nanoparticles for 24 hours. Then the cells were harvested, 
washed and fixed with 4% paraformaldehyde and flow cytometry was performed on these 
samples by BD Canto II flow cytometer. The data was analyzed by using FlowJo software. For 
FNPs, the above procedure was done on TE-71, MIA PaCa2, A549 and OVCAR3 cell lines. As 
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the doped NPs were quenched due to presence of PCBM, the flow cytometer could not detect 
their fluorescence in cells. Imaging and counting cells manually was done instead to get 
quantitative measurements on uptake of doped NPs. (see ‘Imaging’ section) 
 Apoptosis and necrosis quantification after PDT 2.4.7.2
 
1 x 10
6
 cells/ml concentration solutions of TE-71, MIA PaCa-2, A549 and OVCAR3 cell lines 
incubated with 2x10
-4
 mg/ml FNPs for 24 hours. Then the cells were irradiated with 180 J/cm
2
 
light dose and incubated for another 4 hours. Then the cells were harvested and stained with 
annexin V-FITC and PI and kept on ice. Flow cytometry was performed on these samples by BD 
Canto II flow cytometer. The data was analysed by using FlowJo software. 
 
 Imaging  2.5
 
Two types of imaging were done on the samples. The first includes microscopy and the second 
includes the single particle spectroscopy. With microscopy images were acquired to see the 
uptake of nanoparticles in cells, the detection of ROS in cells after PDT, counting of cells for 
uptake quantification, and localization of nanoparticles in cells. 
 2.5.1 Microscopy  
 
 Confocal imaging with laser scanning spinning disc microscope 2.5.1.1
 
The cells administered with doped NPs and CPNPs were imaged with confocal spinning disc 
microscope (Zeiss Axioskop2) with Kr-Ar ion laser. The nanoparticle fluorescence was collected 
using 488 nm laser line and 488/10 band pass filter for excitation. The emission filter used was 
500 LP. For DAPI, fluorescence was collected by using the DAPI filters and the mercury lamp as 
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the excitation source. For CPNPs, to confirm that the CPNPs were inside the cells, confocal 
images at every 0.3 µm were acquired. A selection of these slices was used representing a 
spacing of the slices by 1.5 µm.  
 Epiluminescence imaging  2.5.1.2
 
Imaging was completed with an Olympus IX71 microscope using a 60X objective and Andor 
Zyla sCMOS (DG-152V-C1E-FI) camera. The selection of filters was done by looking at the 
emission and absorption spectra of the nanoparticles and the dyes that are used to stain the cells 
for different experiments. These are explained in the subsections below. Counting the cells for 
uptake quantification was completed by imaging the cells using 20X objective. 
2.5.1.2.1 FNPs uptake  
 
The fixed cells were imaged by epiluminescence microscope (Olympus IX 51) by using 60x 
objective and mercury lamp for fluorescence and FITC filters (excitation filter: 491/10, dichroic 
mirror: 510 DCLP, emission filter: 514 REF) to detect the fluorescence from FNPs and DAPI 
filters (excitation filter: 350/52, dichroic mirror: 405 LP, emission filter: 450/20) to detect 
fluorescence from DAPI stained to nucleus. Phase contrast images were acquired using halogen 
lamp. The nanoparticle images and DAPI images were overlaid using ImageJ (NIH) software. 
The filters were selected by observing the absorbance and emission spectra of the nanoparticles 
and dyes as shown in Figure 2.3. The filters used for detection of nanoparticle fluorescence and 
DAPI fluorescence separate out the fluorescence emission in different channels which then can 
be overlaid to make a complete image. 
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. 
Figure 2.3 Filter selection based on absorbance and emission of nanoparticles and dyes used to 
stain the cells. 
 
2.5.1.2.2 Detection of ROS 
 
The fixed cells were imaged by epiluminescence microscope (Olympus IX 51) by using 60x 
objective and mercury lamp for fluorescence. For CellRox Green Reagent fluorescence the filters 
were used as: excitation filter- 491/10, dichroic filter- 510 DCLP and emission filter- 525/50. For 
CellRox Green Reagent fluorescence the filters were used as: excitation filter- 491/10, dichroic 
filter- 510 DCLP and emission filter- 525/50 To detect the DAPI fluorescence: excitation filter- 
350/52, dichroic mirror- 405 LP, emission filter- 450/20). To detect fluorescence of FNPs: 
excitation filter-488/10, dichroic mirror-510 DCLP and emission filter-600LP were used. Phase 
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contrast images were collected using halogen lamp. The images were overlaid using ImageJ 
software. The filter selection was done as shown in Figure 2.4. 
 
Figure 2.4 Filter selection for fluorescence imaging of CellROX Green Reagent and FNPs. 
 
2.5.1.2.3 Qdot-dopamine probe 
 
Cells fixed after administering the Qdot-dopamine probe, were imaged by (Olympus IX 51) by 
using 60x objective and mercury lamp for fluorescence. The filters used for Qdot fluorescence 
were: excitation filter-350/52, dichroic mirror- 405 LP and emission filter- 400 LP. Phase 
contrast images were collected using halogen lamp. Images were overlaid in ImageJ (NIH). 
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2.5.1.2.4 Endosome and lysosome trackers 
 
The cells were imaged live after staining with early endosome dye and DAPI. Imaging was done 
by Olympus IX 51 microscope by using 60x objective and mercury lamp for fluorescence. 
Endosome fluorescence was collected by using a set of filters as: excitation filter-491/10, 
dichroic mirror- 510 DCLP and emission filter- 525/20. For FNPs the filters used were: 
excitation filter-535/30, dichroic mirror- z514rdc and emission filter- 600 LP. For DAPI: 
excitation filter-350/52, dichroic mirror- 405 LP and emission filter- 450/20 were used. The 
same filters were used when cells were stained with lysotracker dye (Figure 2.5). 
 
Figure 2.5 Filter selection for imaging lysotracker or endotracker dye in cells. 
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 DIC confocal imaging for Qdots 2.5.1.3
 
Confocal images were acquired using an Olympus IX 51 upright microscope with 100X oil 
immersion objective using 405 nm laser (Olympus FV5-LDPSU) for excitation. Fluorescence of 
the probe was collected by Olympus FV5-ZM camera using Olympus fluoview version 4.3 FV 
300 software. Sample of 6.3 µm thickness was scanned with 0.3 µm step size and 21 slices. 
Fluorescence images were collected by emission filter 510LP and 505 DM. Images were 
processed in ImageJ (NIH) software. 
 
 2.5.2 Single particle spectroscopy 
 
Single particle fluorescence images and spectra were collected by using a home-built sample 
scanning confocal microscope. Either the 488 nm laser line from an Ar ion laser or the 375 nm 
diode laser (PicoQuant GmbH, LDH-P-C-375) in combination with a 375/10 excitation filter was 
used as the excitation source depending on the sample. The laser was focused using a Zeiss 100x 
Fluar objective lens (NA 1.3, WD 0.17 mm). The sample was raster scanned across the focused 
laser beam using a Mad City Labs piezoelectric stage (Nano-LP100) to obtain a fluorescence 
image of the sample. The fluorescence was detected by an avalanche photodiode (PerkinElmer 
SPCM-AQR-14). Fluorescence spectra were obtained by a spectrograph (Pl Acton SP-2156) 
with the grating (150 g/mm blaze: 500 nm) centered at 600 nm which was coupled to a 
thermoelectrically cooled electron multiplying charge coupled device (EM-CCD. Andor iXon 
EM+ DU-897 BI). Each fluorescence spectrum was collected with 10 seconds exposure time for 
3 consecutive frames and then averaged. Each spectrum shown in the manuscript is an average 
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built from 50-100 spectra, which were averaged into “ensemble spectra” in Matlab (Mathworks, 
Inc., Natick, Massachusetts).   
 Intracellular spectroscopy in A549 with CPNPs 2.5.2.1
 
With the above set up A549 cells administered with CPNPs were imaged using 488 nm line from 
Ar ion laser. 1 W/cm
2
 laser light was used. The setup included 488 nm interference filter as the 
excitation filter, 495 LP dichroic mirror, and 488 REF as the emission filter.  
 Intracellular spectroscopy in A549 and OVACR3 with Qdots 2.5.2.2
 
A549 and OVCAR3 cells administered with Qdot probe were imaged with 375 nm diode laser. 
The setup included 375 nm interference filter as the excitation filter, 375 nm dichroic mirror. For 
collecting emission to acquire images from cell body (autofluorescence) 480/30 band pass filter 
was used, while for Qdot emission 585/20 band pass filter was used. The images were then 
overlaid in imageJ (NIH). The spectra were collected with 400 LP filter. 
For the MMCNPs, MDA-MB-231 cells were imaged using 375 nm diode laser as the excitation 
source, 375 nm interference filter for excitation filter, 375 nm dichroic mirror and 400 LP for 
collecting emission to aquires images and spectra. 
 SPS on Qdot probe 2.5.2.3
 
For study of restoration of OFF probe by extracellular GSH at particle level each sample was 
drop casted on glass slide and vacuum dried for 10 minutes. The samples used were OFF probe, 
ON probe (after GSH addition) and bare Qdots. 6 µl of diluted sample was placed on a clean 
cover slip and vacuum dried. 375 nm diode laser was used as the excitation source. Dichroic 
mirror used was 375 nm. Fluorescence was collected by 400 LP.    
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 COMPOSITE CONJUGATED POLYMER/FULLERENE CHAPTER 3
NANOPARTICLES AS SENSITIZERS IN PHOTODYNAMIC THERAPY 
FOR CANCER 
 
 Introduction 3.1
 
Innovative and groundbreaking techniques have been developed to treat cancer, ranging from 
surgical removal of cancer cells [13-17] to radiation therapy [5, 6] to chemotherapy with 
anticancer agents [7-10]. Unfortunately, the multitude of factors and forms in which cancer 
appears introduces major challenges in the development of treatment strategies. Issues such as 
drug resistance and lack of site specificity require new treatment methods to be designed and 
investigated that avoid such issues. By combining our current understanding of cancer 
development and function with nanotechnology, new platforms that address these issues can be 
envisioned and developed.  
Recent studies on the development of human cancer have identified reactive oxygen species 
(ROS) as playing a major role in promoting carcinogenesis for a broad variety of cancer cells 
[129-132]. These ROS are also essential participants for normal functioning of cells such as in 
cell signaling and apoptosis but appear at moderate levels. If formed in excessive amount ROS 
can damage normal cells oxidatively leading to cell death [129, 130, 133-135]. Normal cells 
contain protective mechanisms to control ROS levels thereby providing resistance to senescence 
and ROS mediated apoptosis. In contrast, in cancer cells that protection is removed to allow for 
elevation of ROS since cancers require elevated ROS for uncontrolled proliferation. This also 
makes cancer cells more susceptible to ROS induced apoptosis by additional oxidative stress 
caused by external stimuli [136-138]. This double edged sword for human cancer growth and 
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proliferation opens an avenue to selectively target and eliminate cancer cells and tumors that 
exhibit high levels of ROS.  
A number of approaches have been investigated to introduce additional ROS in cancer cells as a 
form of cancer treatment, in particular through photodynamic therapy (PDT). In PDT the level of 
ROS in cells is increased by administering a photosensitizer that absorbs light [139-141]. The 
excited state photosensitizer then relaxes back to the ground state by transfer of a charge or 
energy to the PDT agent. In Type I reactions free radicals are directly formed or superoxide 
anions are formed through oxygen [142]. Type II reactions generate singlet oxygen (
1
O2) by 
energy transfer from the triplet excited state of the photosensitizer to the ground state of oxygen 
(
3
O2), which in turn can form ROS [75, 76, 100, 141, 142].  
While PDT has shown great promise, a major drawback that remains is the non-specific 
distribution of the PDT photosensitizers, which may cause damage to healthy tissue and requires 
patients to avoid exposure to light for periods of time [143, 144]. Nanobiophotonics approaches 
for PDT based on new nanoparticle (NP) designs have brought significant advances to address 
these issues. In this approach, the photosensitizer is delivered by conjugating it with a 
nanoparticle or doping nanoparticles with the photosensitizer [100, 139, 144, 145]. Given the 
promising potential due to for instance multimodality and targeted intracellular delivery that 
could result in increased effectiveness and site specificity of treatment, tremendous research 
effort has been dedicated to this field of research [146-149]. Quantum dots and other inorganic 
nanoparticles have been reported [97, 111, 112, 114]. Magnetic nanoparticles conjugated with 
photosensitizers have been investigated as well [98, 99, 150, 151]. Huang et al. have developed 
silica coated gold nanoclusters to deliver Ce6 (Chlorine-6) photosensitizer into MDA-MB-435 
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cells with promising results [152]. Photosensitizer doped silica nanoparticles were prepared 
though different approaches and studied for PDT application [100, 101, 103]. 
Soft nanoparticles have recently received attention as well.  Virus capsids have been used to 
deliver the photosensitizer in the cells for PDT [153]. Chitosan nanoparticles were developed to 
treat skin cancer by combining PDT and electrochemotherapy [154]. Conjugated polymer 
nanoparticles doped with photosensitizers for PDT were reported first by Grimland et al. [155]. 
In this scheme the conjugated polymer absorbs visible light, or can be excited by two-photon 
excitation (2PE), at which point the excited state conjugated polymer transfers its energy to the 
PDT sensitizer.  This is a promising design since excitation can occur with visible or near-
infrared light either directly or by 2PE [156], and potential issues with intrinsic cytotoxicity can 
be avoided provided the host polymer is biocompatible. De Gao et al. demonstrated that dye 
doped polymer nanoparticles circumvent the intrinsic cytotoxicity of a PDT dye by using a 
biocompatible host polymer matrix [157]. 
In this article we report the fabrication of composite conjugated polymer (poly[2-methoxy-5-(2-
ethylhexyl-oxy)-p-phenylenevinylene], MEH-PPV, (Figure 3.1A) nanoparticles doped with the 
fullerene phenyl-C61-butyric acid methyl ester (PCBM), (Figure 3.1B) for PDT application. In 
this study the conjugated polymer MEH-PPV was used as the host polymer for its high 
extinction coefficient and well-known efficient charge and energy transfer properties to PCBM 
[158]. The doping level was set at 50 wt% PCBM, which is ideal for efficient charge transfer 
between conjugated polymers and fullerenes since the quantum efficiency approaches 1 [159].  
Fullerene has been successfully used for PDT applications in molecular and aggregated 
nanoparticle form [160-165]. However, there are severe intrinsic cytotoxicity issues associated 
with fullerenes [164]. Here we show that the composite MEH-PPV/PCBM nanoparticles are not 
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intrinsically cytotoxic even though fullerene is present, show specificity towards cancer cells, 
yield highly effective PDT treatment at low light doses, and are able to induce apoptosis in 
human ovarian cancer (OVCAR3) in-vitro.  
 
  Results and Discussion 3.2
 
 3.2.1  Nanoparticle fabrication and characterization 
 
 
Figure 3.1 A) Chemical structure of MEH-PPV, B) chemical structure of PCBM, and C) 
absorption and emission spectra of composite MEH-PPV/PCBM NPs in water  
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Figure 3.2 TEM image of 50 wt% PCBM doped MEH-PPV NPs showing the size of NPs. 
 
The polymer-fullerene composite nanoparticles were fabricated by the reprecipitation method as 
reported previously [127]. NP size was characterized by DLS and an average size of 61.5±23.3 
nm was found. The TEM image shown in Figure 3.2 confirmed the size of the doped NPs. The 
zeta potential of these NPs was measured to be -9.66±8.12 mV implying a neutral to slightly 
negatively charged surface. This neutral to slightly negatively charged surface state may play a 
role in the observed specificity of the NPs to cancer cells (vide infra) since positive surface 
charge leads to preferential uptake by many normal cell lines [166-168]. The size range we can 
obtain with these NPs (~20-100 nm) [127] is ideal for internalization [169-171]. Figure 3.1 C 
shows the absorption and emission spectra of NPs in water. The absorption maximum is located 
at 498 nm. MEH-PPV is intrinsically fluorescent and the emission maximum is located at 586 
nm for MEH-PPV in NPs. However, the emission from blended NPs is quenched due to the 
charge transfer from MEH-PPV to PCBM [127, 158, 172]. The fluorescence emitted by the NPs 
is still easily detected with sensitive detectors due to the dynamic nature of the quenching 
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process and the large number of available chromophores [172, 173], but may limit general 
applicability for e.g. in-vivo tracking.  
 
 3.2.2  Evaluation of nanoparticle uptake  
 
The extent of uptake of the NPs was determined by confocal fluorescence imaging. Fluorescence 
and corresponding phase images are shown in Figure 3.3. Although the NPs are quenched (vide 
supra), the fluorescence from NPs can be seen in the OVCAR3 cell line, and to a lesser extent in 
A549 and MDA-MB-231 cell line. There is no detectable fluorescence of NPs observed in the 
TE-71 cell line. These data suggest that the TE-71cell line either uptakes a very low amount of 
NPs or no NPs at all, while the cancer cell lines take up significant amounts of NPs. This 
apparent selectivity in uptake between normal and cancer cell lines can be explained on the basis 
of surface charge on the NPs and on the cell membrane, and differences in metabolic rate or 
aggressiveness between the normal cells and cancer cells.  
60 
 
 
Figure 3.3 Confocal fluorescence images and corresponding phase contrast images of TE-71, 
MDA-MB-231, A549, and OVCAR3 incubated with 2x10
-4
 mg/ml composite MEH-PPV/PCBM 
NPs for 24 hours in dark. NP uptake increases in the order TE-71 < MDA-MB-231 < A549 < 
OVCAR3. The phase contrast images show that the morphology of the cells is not affected by 
the presence of NPs 
 
The NPs exhibit a zeta potential of -9.66±8.1mV and so are neutral to slightly negatively 
charged. It has been shown that cancer cells have less negative charge on their surfaces as 
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compared to normal cells [174], which allows NPs to have more interaction with cancer cells 
than with the normal cells. The higher metabolic rate of cancer cells also favors higher uptake of 
NPs compared to normal cells [131, 175-177]. Quantification of nanoparticle uptake was not 
successful by flow cytometry due to weak nanoparticle fluorescence (Figure 3.4) 
 
Figure 3.4 Flow cytometry for quantitative uptake of NPs in A) TE-71, B) MDA-MB-231, C) 
A549 and D) OVCAR3. Due to the quenched NPs the fluorescence of NPs was not detectable by 
flow cytometer 
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Figure 3.5 Quantification of NPs uptake by different cell lines by cell counting in images. A) left 
column is images of DAPI channel for total cells counted and right column is NPs fluorescence 
channel for cells with NPs, B) bar graph for showing % cell population having NPs. 
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The quantitative measurements on uptake of NPs by different cell lines were completed by cell 
counting by imaging instead. Figure 3.5 shows the representative images for each cell line. The 
total number of cells counted was calculated my counting the nuclei stained by DAPI. The 
number of cells which have NPs was decided by counting the fluorescence of NPs in cells. At 
least 4 number of fields were taken for counting the cells. The total number of cells for each cell 
line was above 500. The number of 1) total cells counted, 2) cells with NPs, 3) % cells with NPs 
and 4) fields of view are summarized in 
Table 3.1  
Table 3.1 Number of total cells counted, cells with NPs, fields of view and % cells with NPs. 
 
 
Among the cancer cell lines differences in uptake are also observed, which is attributed to 
differences in the aggressiveness of the cancer cell lines. With increase in metabolic rate of the 
cell line, the uptake of NPs is also expected to increase. It is well known that the OVCAR3 cell 
line is more aggressive than MDA-MB-231 or A549 [176, 178]. We also considered that the 
uptake mechanism could play a role in the variation of uptake of NPs by different cancer cell 
Cell line TE-71 MDA-MB-231 A549 OVCAR3 
Total cells 715 646 1035 1063 
Cells with NPs 6 85 944 913 
Field of view 5 6 4 6 
% cells with NPs 0.8 13 91 85 
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lines. It is well known that the uptake of nanoparticles of size up to 200 nm is mainly by clathrin- 
and claveolae-mediated endocytosis, and by pinocytosis or macropinocytosis [111]. Positively 
charged NPs are uptaken by all the three of these endocytic pathways while negatively charged 
NPs are uptaken only by clathrin and caveolae-mediated pathways and not by pinocytosis [111]. 
Specifically, it has been shown that for A549 NPs are uptaken only by clathrin-mediated 
endocytosis [65] while for OVCAR3 NPs go through an energy dependent uptake pathway 
[179], which can be any or all of the three pathways discussed above. From these reports it can 
be speculated that the high uptake by OVCAR3 is due to the involvement of clathrin- and 
caveolae-mediated endocytosis, and macropinocytosis. In contrast, for A549 and MDA-MB-231 
NP uptake proceeds only by clathrin or caveolae mediated endocytosis, which may result in 
lower amounts of NP uptake.  
 
 3.2.3  Evaluation of intrinsic nanoparticle cytotoxicity 
 
Intrinsic cytotoxicity of the NPs was first evaluated qualitatively by confocal imaging. The phase 
contrast images in each panel in Figure 3.3 show that the morphology of the cells is not changed 
after uptake of NPs. The in-vitro cytotoxicity of these NPs was subsequently determined 
quantitatively by cell viability MTT assays. The MTT assays were completed by administering 
three doses of NPs to each of the four cell lines and evaluating the relative proliferation for 96 
hours in comparison with the untreated cell lines as control (0 mg/ml NPs dose for each cell 
line). It can be seen from Figure 3.6 that at the lowest dose of NPs all the cell lines have cell 
viability that is near 100%. At 2x10
-4
 mg/ml there is minor cell death immediately upon adding 
NPs. However, the cell population regrows normally afterwards. For the MDA-MB-231 cell line 
the maximum tolerable dose is between 2x10
-4
 and 3.6x10
-4
 mg/ml.  
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Figure 3.6 Results of MTT viability assays completed for cells incubated with NPs in dark. 
Three NP doses and a control were evaluated for each cell line (A) TE-71, B) MDA-MB-231, C) 
A549, and D) OVCAR3). Incubation times in dark of 0, 24, 48, 72, and 96 hours were 
considered.  
 
 
0
20
40
60
80
100
120
0 mg/ml 0.4 mgml 2 mg/ml 3.6 mg/ml
P
e
rc
e
n
t 
ce
ll 
vi
ab
ili
ty
Dose of NPs
10-4 mg/ml
TE-71
0 hrs
24 hrs
48 hrs
72 hrs
96 hrs
A
0
20
40
60
80
100
120
0 mg/ml 0.4 mgml 2 mg/ml 3.6 mg/ml
P
e
rc
e
n
t 
ce
ll 
vi
ab
ili
ty
Dose of NPs
10-4 mg/ml
MDA-MB-231
0 hrs
24 hrs
48 hrs
72 hrs
96 hrs
B
0
20
40
60
80
100
120
0 mg/ml 0.4 mgml 2 mg/ml 3.6 mg/ml
P
e
rc
e
n
t 
ce
ll 
vi
ab
ili
ty
Dose of NPs 
10-4 mg/ml
A549
0 hrs
24 hrs
48 hrs
72 hrs
96 hrs
C
0
20
40
60
80
100
120
0 mg/ml 0.4 mgml 2 mg/ml 3.6 mg/ml
P
e
rc
e
n
t 
ce
ll 
vi
ab
ili
ty
Dose of NPs
10-4 mg/ml
OVCAR3
0 hrs
24 hrs
48 hrs
72 hrs
96 hrs
D
66 
 
At 3.6x10
-4
 mg/ml the viability of this cell line is 0, which suggests that at this concentration the 
NPs are cytotoxic to the MDA-MB-231 cell line while for the other cell lines considered here no 
cytotoxicity is observed. Thus, the MDA-MB-231 cell line appears to be unusually sensitive to 
the presence of the composite NPs compared to the other cancer cell lines. Since the normal 
control is unaffected it can be suggested that the composite NPs have anticancer properties 
specific to the MDA-MB-231 cell line at the 3.6x10
-4
 mg/ml dose that may merit further study. 
The normal proliferation of the cell lines in presence of NPs when kept in dark can also be 
plotted in a way shown in Figure 3.7. The cells can be seen to proliferate normally upto 96 hours. 
 
Figure 3.7 Proliferation of cell lines in presence of different doses of NPs as compared to control 
dose (0 mg/ml) upto 96 hours. MDA-MB-231 cell line is eradicated at highest dose of NPs. 
 
 3.2.4  Composite conjugated polymer/PCBM nanoparticle photodynamic therapy 
 
  Quantitative evaluation 3.2.4.1
 
Effectiveness of PDT based on the composite conjugated polymer/PCBM NPs was quantified by 
MTT assays. Each of the four cell lines was incubated with three different doses of NPs. Each 
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sample type (12 total) was treated with three different doses of light (36 data points). In addition, 
the experiments described above were completed in four replicates so that after each period of 
irradiation with light, samples could be tracked for four different incubation times (i.e. 
incubation in dark after irradiation). The latter experiment was completed to determine the time 
frame for treatment to be effective, since once elevated ROS levels are generated through PDT, 
these levels will not dissipate instantaneously after PDT has been completed. Controls were 
completed in the absence of NPs (36 data points). An additional control experiment was 
completed to prove the formation of ROS upon PDT. The presence of ROS was confirmed 
immediately after PDT and after post-PDT dark incubation (2 hours) with CellROX Green 
Reagent, as shown in Figure 3.8. These data support that photo-induced cell death are related to 
an ROS mechanism. Figure 3.9 shows the data obtained from MTT assays. The panels A, B, C 
and D in Figure 3.9 show the cell viabilities for the samples collected after post-PDT incubation 
times (in dark) of zero hours (i.e. immediately following PDT), and after post-PDT incubation 
times of 2, 4 and 12 hours. In each panel the cell viabilities at three doses of NPs and three doses 
of light are shown together with the controls (no NPs). Data are represented with respect to the 
corresponding controls, which are assumed as 100% viable. Immediately following PDT (zero 
hours post-PDT incubation in dark), the viability for the TE-71 control cell line decreases at most 
20%, cell viability for MDA-MB-231 also decreases up to 20%, for A549 a decrease up to 30% 
is observed, and for OVCAR3 a decrease in cell viability up to 70% is observed. Phototoxicity 
controls (vide infra) show no cell death upon light exposure, so up to 20% decrease in cell 
viability for TE-71 suggests that a small amount of NPs were taken up. After 4 hours post-PDT 
incubation in dark the data remain unchanged for TE-71, MDA-MB-231 shows an additional 5% 
decrease, effectiveness for A549 doubled (from up to 30% to up to 60% cell death), and for 
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OVCAR3 near complete (95-100%) cell death is observed for the 2x10
-4
 mg/ml and 3.6x10
-4
 
mg/ml NP doses at light doses > 60 J/cm
2
. 
 
Figure 3.8 Detection of ROS in A549 and OVCAR3 cells using CellROX green reagent.  
Epiluminescence and phase contrast images of A) Negative control: no NPs dose and no light 
dose, B) Negative control: no NPs dose, 180 J/cm
2
 light dose and 2 hours post-PDT incubation, 
C) Negative control: 2x10
-4
 mg/ml NPs dose and no light dose, D) Samples with 2x10
-4
 mg/ml 
NPs dose and 180 J/cm
2
 light dose with 0 hours post-PDT incubation, E) Samples with 2x10
-4
 
mg/ml NPs dose and 180 J/cm
2
 light dose with 2 hours post-PDT incubation, F) Positive control 
performed with 100µM H2O2 
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Figure 3.9 Results for MTT cell viability assays for the TE-71, MDA-MB-231, A549, and 
OVCAR3 cell lines after completion of composite MEH-PPV/PCBM based PDT. Three doses of 
NPs and a control (no NPs), and three doses of light were studied. In addition, four post-PDT 
incubation times,A) 0 hours, B) 2 hours, C) 4 hours, and D) 12 hours were considered   
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Data for 12 hours post-PDT incubation in dark appear nearly identical to the data for 4 hours 
post-PDT incubation in dark. Differences between the effectiveness of treatment between the 
MDA-MB-231, OVCAR3 and A549 cancer cell lines observed in-vitro are attributed to the 
difference in nanoparticle uptake between these cell lines (vide supra). These data first of all 
suggest high effectiveness of the composite MEH-PPV/PCBM NP based PDT for the A549 and 
OVCAR3 cell lines, while MDA-MB-231 shows only moderate effects except for the 3.6x10
-4
 
mg/ml NP dose (already observed in dark). As discussed above (vide supra), this may suggest 
that the composite NPs have anticancer properties specific to the MDA-MB-231 cell line at the 
3.6x10
-4
 mg/ml NP dose that warrant further study. Second, composite MEH-PPV/PCBM NP 
based PDT reaches its full potential for effectiveness within 4 hours. Third, the 120 J/cm
2
 light 
dose in most instances appears to have a very similar effectiveness compared to the 180 J/cm
2
 
light dose (which corresponds to the exposure to full direct sunlight measured at sea level, minus 
UV portion of spectrum which we filtered, out experienced for 30 minutes). The 180 J/cm
2
 light 
dose presents a practical upper limit for the light dose needed for effective composite MEH-
PPV/PCBM NP based PDT. Fourth, while cell viability decreases as the dosage of NPs increases 
from 0.4x10
-4
 to 2x10
-4
 mg/ml, effectiveness plateaus at the 3.6x10
-4
 mg/ml NP dose. Thus the 
2x10
-4
 mg/ml NP dose proved to be the most efficient dosage of NPs. Finally, the high 
effectiveness of the PDT based on the composite conjugated polymer/PCBM NPs for A549 and 
OVCAR3 compared to MDA-MB-231 and the control line (TE-71) indicates again the 
reasonably selective uptake (especially considering no surface functionality) of the NPs by 
certain cancers as discussed above.   
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  Live-dead imaging and qualitative evaluation 3.2.4.2
 
Further insight in the composite MEH-PPV/PCBM NP based PDT was gained by fluorescence 
imaging using a live/dead staining scheme and phase imaging. In addition, these samples were 
also stained with propidium iodide (PI) and FITC-annexin V to observe necrosis and apoptosis, 
respectively. Cell lines were again treated with nanoparticles and three different light doses.  
 
Figure 3.10 Live/dead stain epiluminescence imaging for observation of apoptotic (FITC-
annexin V, green) and necrotic cell (PI, red) death induced by composite MEH-PPV/PCBM 
based PDT. Cell nuclei were stained with DAPI (blue). The cell lines TE-71, MDA-MB-231, 
A549 and OVCAR3 were treated with a 2x10
-4
 mg/ml NP dose and underwent PDT treatment at 
three light doses (columns labeled 60, 120, and 180 J/cm
2
).  Post-PDT incubation time was 4 
hours.  Necrotic death is observed by the purple color of the nucleus due to mixing of red and 
blue channels upon overlaying the fluorescence images.  The fluorescence images are overlayed 
on the corresponding phase contrast images to observe cell morphology simultaneously.  Control 
data are shown in the left column (no NPs, no exposure to light, i.e. normal control) and the right 
column (no NPs, exposure to light, i.e. phototoxicity control) 
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Based on the quantitative analysis, we settled on the 2x10
-4
 mg/ml NP dose for this experiment.  
Two controls, cells without NPs kept in dark (dark control) and cells treated with light in the 
absence of NPs (phototoxicity control), were studied as well. The data (Figure 3.10) again show 
that treatment of OVCAR3 (which takes up the most nanoparticles) is the most effective. At the 
120 J/cm
2
 light dosage apoptosis and necrosis is observed, while at the higher light dosage only 
necrosis is observed. Cell morphology clearly indicates treatment induced death. Similar 
observations are made for A549, but less dramatic due to the somewhat lower uptake of 
nanoparticles by that cell line and only necrosis is observed. The TE-71 cell line is not affected 
by treatment except at the highest light dosage when considering cell morphology. The PI and 
FITC-annexin V stains give a negative result, however, and the cell morphology appears pristine 
in all other cases. The same observation is made for MDA-MB-231. The control shows no 
observable cell damage. The PI and FITC-annexin V stains give a negative result and the cell 
morphology appears pristine for all controls.   
In addition, the data clearly show that the A549 cell line only undergoes necrosis while the 
OVCAR3 cell line shows apoptosis at 60 and 120 J/cm2 and necrosis at 180 J/cm2. Apoptosis is 
a programmed cell death important in maintaining the growth and immune responses of the body 
[180, 181]. During the genetic mutations in normal cells that lead to development of cancer, the 
cell loses the ability to undergo apoptosis, which is often due to mutation of the p53 gene. This 
process is responsible for tumor development by postponing the death of cancer cells. If a 
treatment can induce or enhance apoptosis in cancer cells then the likelihood of successful long 
term treatment increases significantly, because the potential for regrowth of cancer cells and 
tumor tissue between treatment sessions becomes much smaller [180, 182, 183]. Based on the 
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findings of this live/dead imaging experiment, the cancer treatment strategy discussed herein has 
shown very promising in-vitro results for A549 and even more so for OVCAR3. 
 
 . Conclusion 3.3
 
Photodynamic therapy based on composite MEH-PPV/PCBM NP as a source of ROS has been 
shown to be a highly effective treatment approach for cancer cell lines in-vitro.  The all-organic 
nanoparticles are not cytotoxic at doses effective for PDT, and present a treatment scheme that is 
benign to normal non-cancerous cells. PDT by means of the composite MEH-PPV/PCBM NP 
works under relatively low light conditions for reasonable short exposure times due to the high 
absorption cross-section of the polymer nanoparticles, thus avoiding phototoxicity. It is fully 
effective in a single treatment for ovarian cancer cells and about 60% effective for A549 cancer 
cells 4 hours after treatment was initiated in-vitro, and already shows specificity to cancers 
without surface modification. In-vitro a nanoparticle dose of 2 x 10
-4
 mg/ml together with a light 
dose of 180 J/cm
2
 is already sufficient to observe these results 4 hours after treatment for A549 
and MDA-MD-231. For OVCAR3 a light dose of 120 J/cm
2
 is sufficient, and apoptosis is 
observed as a mechanism of cell death induced by PDT based on composite MEH-PPV/PCBM 
NP. The latter is a promising finding for potential development of treatment for ovarian cancer 
by the PDT scheme discussed herein.   
Quantitative differences between the effectiveness of treatment between the MDA-MB-231, 
OVCAR3 and A549 cancer cell lines observed in-vitro can be attributed mainly to the difference 
in nanoparticle uptake between these cell lines. Further improvement of targeting of the 
nanoparticles to cancers will be investigated in the near future. 
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 CONDUCTING POLYMER NANOPARTICLES FOR PDT CHAPTER 4
 
 Introduction  4.1
 
Chemotherapy [7-11], surgery [3, 4, 184] and radiotherapy [5, 6] are currently widely used in 
clinical settings for treatment of cancer. Multimodal treatments such as chemotherapy combined 
with immunotherapy [185, 186] or with radiotherapy [187] are also used. Research on further 
treatment development is also ongoing. Surgery has recently seen improvements by the 
development of laser surgery [13-17] and fluorescence imaging guided surgery[18, 188]. Small 
molecules such as doxorubicin [21, 56, 189] and STAT3 inhibitors [34, 36, 190, 191] and 
nanoparticle drugs [50, 192]are currently under investigation.  In addition, photodynamic therapy 
(PDT) has been shown to be a promising treatment scheme for cancer through clinical trials and 
preliminary application at treatment centers [193-198].   
In PDT a photosensitizing material is internalized by cancer cells, and subsequently these cells 
are irradiated with light. The photosensitizer generates Reactive Oxygen Species (ROS) under 
irradiation that can induce oxidative stress and structural damage in cancer cells, with the aim to 
achieve cell death [75, 76, 82, 199, 200]. For normal cells, ROS are essential in the regulation of 
cell functions such as cell signaling and apoptosis. ROS levels are kept in check under normal 
circumstances by intrinsic antioxidants present in cells. Studies on formation of cancerous cells 
have shown that when ROS levels increase to an extent where they can no longer be removed by 
the intrinsic antioxidants present in cells, this condition can lead to cancer [129-132]. As such, 
cancer cells need elevated amounts of ROS for proliferation, but at the same time cancer cells do 
not have sufficient antioxidants to scavenge ROS. Thus even while cancer cells thrive with 
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elevated ROS levels, they are also very susceptible to externally stimulated elevations of ROS 
levels [136-138, 177]. 
Developments in nanotechnology inspired photosensitizers have brought new developments to 
PDT. Various inorganic nanoparticle photosensitizers such as quantum dots[111, 112], gold 
nanoparticles [96, 97, 113] magnetic nanoparticles [98, 99], silica nanoparticles [100-103], and 
titanium oxide nanoparticles [114] have been developed and studied.  A few examples of organic 
nanoparticle photosensitizers such as methacrylate polymer nanoparticles doped with verteporfin 
as the photosensitizers and polymeric micelles of block copolymer poly(ethylene glycol)–co-
poly(D,L-lactic acid) (PEG-PLA) loaded with 5,10,15,20-tetrakis(mesohydroxyphenyl)porphyrin 
(mTHPP) as the photosensitizer have been reported [105, 201]. Liposomes doped with various 
photosensitizers have been studied for application in PDT [106]. Aminolevulinic acid 
encapsulate liposomes were recently reported for PDT application [202]. Phthalocyanine 
conjugated polypropylenimine dendrimers, and porphyrine phthalocyanine decorated dendrimers 
[107, 108] have also been reported.  
Recently, photosensitizer-doped conducting polymer nanoparticles have received attention as 
potential photosensitizers for PDT. Photosensitizer doped conjugated polymer nanoparticles 
were developed and characterized by Grimland et al. Singlet oxygen formation by 
tetraphenylporphyrine (TPP) photosensitizer under one- and two-photon excitation was proven 
by UV-vis spectroscopy, and DNA damage as proof-of-concept was shown by these authors. 
[155]. Shen et al. concurrently proved the formation of singlet oxygen for tetraphenylporphyrine 
(TPP) photosensitizer doped conjugated polymer nanoparticles by singlet oxygen 
luminescence[110]. Zhang et al. more recently followed a similar nanoparticle design scheme 
with meta-tetra-(hydroxyphenyl)-chlorin (m-THPC) as photosensitizer to produce ROS[203].  
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In this article, conducing polymer nanoparticles fabricated from the conducting polymer poly[2-
methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV Fig. 1A) were studied for 
application in PDT. Photosensitization was found to be intrinsic to these conducting polymer 
nanoparticles (CPNPs) without the use of photosensitizer dopants. These CPNPS were 
investigated in-vitro for their potential application in PDT for cancer treatment. The CPNPs show 
bright emission in-vitro that enables fluorescence imaging of internalized CPNPs. It was 
observed that these CPNPs have a strong intrinsic bias towards the cancer cell lines studied here 
without surface modification. The CPNPs were observed to be not intrinsically cytotoxic (no 
cytotoxicity observed in dark), and show very promising PDT results. PDT was highly effective 
for lung and ovarian cancer at moderate intensities of visible light, without observation of 
phototoxicity.  
 
 Results and discussion 4.2
 
 4.2.1 CPNP fabrication and characterization 
 
The CPNPs were prepared by the reprecipitation method [127, 128, 204]. The resulting CPNPs 
are small quasi-spherical clusters of about 20 to 50 polymer chains [205]. DLS data show that 
the CPNPs have an average size of 34±6 nm in diameter with a narrow size distribution (Figure 
4.1 B), consistent with our previous reports [127]. The size of CPNPs was confirmed by TEM as 
shown in Figure 4.2. The zeta potential of the CPNPs is -12.4 ± 3.7mV, showing that the CPNPs 
surface have slight negative to no charge. The absorption and emission spectra of CPNPs 
suspended in water shown in Figure 4.1 C depict a broad range of absorption in the visible 
spectrum having an absorption maximum at 494 nm and an emission maximum at 591 nm, 
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respectively. The CPNPs were observed to be stable in cell culture media for 96 hrs as 
previously documented by Wu et al[205] 
 
Figure 4.1 A) Structure of MEH-PPV polymer, B) DLS showing size of CPNPs, and C) 
Absorption (red line) and emission (black line) spectra of CPNPs.  
 
 
Figure 4.2 TEM image of CPNPs to show the size of the nanoparticles. 
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 4.2.2 In-vitro evaluation of CPNP uptake 
 
Spherical nanoparticles of around 30 nm in diameter [169-171] and with positive zeta potential 
on their surfaces are typically uptaken easily by cells [166-168, 174, 206-208]. The size range is 
approximated well by the CPNPs discussed herein, while the surface charge is not ideal for 
cellular uptake, the small magnitude of the negative charge on the CPNPs was observed to 
actually contribute to desirable selectivity in uptake (vide infra). Figure 4.3 shows the confocal 
fluorescence images and corresponding phase contrast images of the cell lines incubated with 4 
doses of CPNPs (0 mg/ml, 0.4 x 10
-4 
mg/ml, 2 x 10
-4
 mg/ml and 3.6 x 10
-4
 mg/ml), revealing 
significant CPNP uptake. It can be seen that the different cell lines take up different amounts of 
CPNPs and that the uptake is dose dependent. Cancer cell lines abundantly take up nanoparticles 
in comparison to the normal control cell line. The quasi-selective uptake by cancer cell lines over 
the control cell line can be attributed to the charge on the surface of CPNPs (slight negative to 
neutral) and on the cell membranes. It has been reported that the charge on normal cell lines is 
highly negative whereas the cancer cell lines have less negative charge on them [174, 209]. Due 
to lesser negative charge on the cell surface of cancer cells the CPNPs have less repulsion from 
the cancer cell line surfaces as compared to the normal cell lines. Comparing the cancer cell 
lines, OVCAR3 has the highest uptake followed by A549 and lastly MDA-MB-231. The high 
uptake of CPNPs by OVCAR3 cells can be attributed to the aggressiveness of this cell line [135, 
175, 176, 178]. 
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Figure 4.3 From top to bottom confocal fluorescence images and corresponding phase contrast 
images of TE-71, MDA-MB-231, A549 and OVCAR3 cells incubated with increasing doses of 
CPNPs. CPNP doses are indicated at the top of the figure and are expressed in units of 10
-4
 
mg/ml. Green dots represent the fluorescence from CPNPs and the blue color indicates nuclei 
stained with DAPI. 
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CPNP uptake efficiency was further quantified by flow cytometry. Figure 4.4 A-D shows 
normalized histograms indicating the distribution of fluorescence intensity detected for cells 
incubated with CPNPs. All cell lines appear to have taken up nanoparticles, although there is an 
apparent difference in extent of uptake. For clarity, the flow cytometry data (fraction of 
population that took up nanoparticles and detected fluorescence intensity) were replotted as bar 
graphs in Figure 4.4E-F. The percent cell population that has internalized CPNPs is shown in 
Figure 4.4E. The data show that 68.2% of TE-71 cells internalized CPNPs, while for MDA-MB-
231, A549, and OVCAR3 81.6%, 85.6%, and 90.05% of the cells internalized CPNPs. The 
average fluorescence intensity of CPNPs in each cell line is shown in Figure 4.4F. The low 
average fluorescence intensity observed for TE 71 implies that even though there are 68.2 % 
cells which have internalized CPNPs, the amount of CPNPs in each cell is very small. The 
OVCAR3 and A549 cell lines exhibit comparable average fluorescence intensity of CPNPs 
followed by MDA-MB-231. The flow cytometry data thus confirm the qualitative observations 
made by fluorescence imaging (Figure 4.3). 
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Figure 4.4 Flow cytometry data on uptake of CPNPs by each cell line. Representative data 
showing normalized cell count of A) TE 71, B) MDA-MB-231, C) A549 and D) OVCAR3 cell 
lines with respect to detected CPNP fluorescence. E) Percentage of the cell population for each 
cell line that has internalized CPNPs (green bars) together with controls (red bars, no CPNPs, 
n=2), F) Average fluorescence intensity detected from CPNPs for each cell line depicted by 
green bars, together with controls (red bars, no CPNPs, n=2) 
 
To confirm that the CPNPs were indeed internalized as opposed to being stuck to the outside cell 
membrane, 3D confocal imaging experiments were completed. CPNPs are detected in the 
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intracellular environment throughout the 3D stack of images, as shown in Figure 4.5 using A549 
as a representative example. Similar results were obtained for each cell line studied herein. These 
images show that the CPNPs are located mostly at the periphery of the nucleus. 
 
Figure 4.5 Confocal slices of an A549 cell with CPNPs (green dots) at the periphery of the 
nucleus (blue). 
 
The stability of the CPNPs inside the cells was evaluated by Single Particle Spectroscopy. The 
A549 cell line was selected for this experiment, since it internalizes CPNPs but not to the extent 
that individual particles or clusters cannot be identified. Figure 4.6A and B show the brightfield 
and fluorescence image of a single A549 cell that internalized CPNPs. The expanded image in 
Figure 4.6C allows for the observation of single CPNPs and clusters of CPNPs. These were 
individually addressed by confocal laser and emission spectra were collected for 100 
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CPNPs/CPNP clusters. The resulting single particle ensemble spectrum is shown in Figure 4.6 D. 
 
Figure 4.6 Single particle imaging and spectroscopy on CPNPs inside A549 cells. A) Bright field 
image of an A549 cell, B) Raster-scanned fluorescence image of the corresponding A549 cell 
with CPNPs inside the cell. The CPNPs can be seen clearly as spherical bright spots in the 
magnified region of the image shown in panel C). D) The ensemble spectrum of CPNPs inside 
the cell (black line) has max at 588nm. The spectral shape and emission maximum indicate that 
the CPNPs remain stable in the intracellular environment. The inset in D) shows the 
autofluorescence of the cell with max 550nm. A shoulder at this wavelength can be seen in the 
spectrum of CPNPs. 
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The peak emission at 588 nm is comparable to the peak emission at 591 nm observed for freshly 
prepared CPNPs measured in water. Conversely, well dissolved MEH-PPV in a good solvent 
emits around 553 nm [127]. These data confirm that the CPNPs are stable and intact inside the 
cell. 
 
 4.2.3 Intrinsic cytotoxicity of CPNPs 
 
The intrinsic cytotoxicity of the CPNPs was evaluated quantitatively by MTT assays. Figure 4.7 
shows MTT data for the four cell lines incubated with three doses of CPNPs (0.4x10
-4
 mg/ml, 
2x10
-4
 mg/ml and 3.6x10
-4
 mg/ml) together with the control (0 mg/ml). At no point is intrinsic 
cytotoxicity of CPNPs observed. The cells proliferate normally in presence of CPNPs as 
compared to the control dose. These data suggest that no ROS are formed in dark (vide infra), in 
contrast to other sensitizers such as quantum dots, which even in the absence of light can still 
lead to elevated ROS levels in cells, and cause damage to cell organelles or lead to cell death 
[210, 211]. The data was also plotted in a way to show the normal proliferation (Figure 4.8 A). 
The image shown in Figure 4.8 B shows normal functioning of the cells even when the CPNPs 
are inside the cells. 
As can be seen from the image, the dividing cells shown in yellow circle seem to share the 
nanoparticles shown in green color. This suggest that the cells function normally without any 
interference by the nanoparticles. Also, even if the cells are multiplying during the incubation 
period, the sharing of nanoparticles will leave all the cells with nanoparticles in them.  
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Figure 4.7 MTT viability assays to evaluate the intrinsic cytotoxicity of CPNPs. A) TE-71, B) 
MDA-MB-231, C) A549 and D) OVCAR3 with control dose (0 mg/ml) and three doses of 
CPNPs (0.4x10
-4
 mg/ml, 2x10
-4
 mg/ml and 3.6x10
-4
 mg/ml). The incubation periods are 0, 24, 
48, 72 and 96 hours. 
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Figure 4.8 A) MTT data to show normal proliferation of different cell lines in presence of 
different doses of CPNPs as compared to the control dose (0 mg/ml) upto 96 hours, B) an image 
of OVCAR3 cell line administered with CPNPs. Green color is the fluorescence of CPNPs.and is 
overlid o phase contrast image. Dividing cell is shown in yellow circle.  
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 4.2.4 PDT 
 
Figure 4.9 shows MTT data quantifying the viability of the four studied cell lines after PDT. The 
cell lines were incubated with three different doses (0.4x10
-4
 mg/ml, 2x10
-4
 mg/ml and 3.6x10
-4
 
mg/ml) of CPNPs and then exposed to different light doses (60 J/cm
2
, 120 J/cm
2
 or 180 J/cm
2
). 
These moderate light doses are sufficient for an effective PDT treatment, [76, 193, 212, 213], 
and are possible due to the large absorption cross section of MEH-PPV used herein in the visible 
spectrum (> 10
6
 L/mol cm
-1
). No phototoxicity effects were observed in these studies (vide infra) 
Evaluation of treatment results was completed immediately after the PDT application (Figure 
4.9A), and after an incubation (waiting) period of 2 hours (Figure 4.9B), 4 hours (Figure 4.9C), 
and 12 hours (Figure 4.9D). In each panel (A, B, C and D) the cell viability at three CPNP doses 
and three light doses are compared with the control for each cell line (0 mg/ml CPNPs). 
The cell viability in each panel decreases from TE-71 to MDA-MB-231 to A549 to OVCAR3. In 
addition, for each cancer cell line, viability decreases with increasing CPNP dose, although the 
highest dose (3.6x10
-4
 mg/ml) does not show significant improvement. For TE71 there is no 
significant CPNP dose response due to the limited CPNP uptake. For A549 and OVCAR3 
dependence on the light dose is also observed, where increasing light dose results in lower 
viability. The 180 J/cm
2
 light dose still shows measurable improvement in reducing cell viability 
in those cases. This observation can again be attributed to the limited CPNP uptake by TE71 and 
MDA-MB-231 in comparison to A549 and OVCAR3.  
.  
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Figure 4.9 MTT assay to evaluate the cell viability after application of PDT. Post-PDT 
incubation period A) 0 hours, B) 2 hours, C) 4 hours, and D) 12 hours. Each panel has four cell 
lines, TE-71, MDA-MB-231, A549 and OVCAR3. Each cell line is administered with three 
doses of CPNPs (0.4x10
-4
 mg/ml, 2x10
-4
 mg/ml and 3.6x10
-4
 mg/ml) and 0 mg/ml as the control 
dose. The colored bars represent light doses (red: 60 J/cm
2
, green: 120 J/cm
2
, blue: 180 J/cm
2
). 
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In contrast, the higher amount of CPNPs uptaken by cells lines such as A549 and OVCAR3 will 
lead to higher amounts of ROS being generated upon irradiation, which is reflected in the 
observation of low cell viability. It is, however, not possible to rule out the effects of differences 
in inherent ROS levels of different cell lines on susceptibility to undergo oxidative stress through 
PDT [214, 215]. Overall, effectiveness of PDT scales with the extent of CPNP uptake and 
administered light dose. The 2x10
-4 
mg/ml dose of CPNPs under light dose of 180 J/cm
2 
was 
found to be most effective. For the OVCAR3 cell line cell viability is near zero under these 
conditions. 
 
 4.2.5 CPNPs as the source of ROS 
 
It’s been previously shown that conducting polymers are able to charge- and energy transfer 
from their triplet excited state to the ground state of oxygen to form singlet oxygen [216-218]. 
The rapid photobleaching of conducting polymers, both reversible and irreversible, has been 
attributed to this mechanism [219]. It was therefore hypothesized that CPNPs could yield ROS 
formation upon photoirradiation without the need for photosensitizer dopants. Specifically, upon 
exposure to light the CPNPs are photoexcited and in the case of MEH-PPV have an 
approximately 1.25% probability of intersystem crossing to the triplet excited state [220] . 
Oxygen can deactivate the latter by energy transfer, which results in excitation of the oxygen 
triplet ground state to the highly oxidative singlet oxygen excited state (Type II 
photosensitization) [75, 76, 81, 82]. Alternatively, oxygen or other substrates such as solvent- 
and biomolecules can accept an electron from the triplet excited state to form radicals (Type I 
photosensitization) [75, 76, 81, 82]. It has previously been shown that conducting polymers can 
interact directly with oxygen to form superoxide in a reversible fashion [221-223]. 
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Figure 4.10 Epiluminescence images with corresponding phase contrast images of A549 and 
OVCAR3 cell lines for detection of ROS in by CellRox green reagent. A) Control in absence of 
treatment (no CPNPs, no light). B) Negative control by means of light exposure in absence 
CPNPs. C) Negative control by means of incubation with CPNPs in absence of light exposure. 
CPNP emission can be detected. D) Fluorescence images taken immediately after PDT, and E) 2 
hours post-PDT. F) Positive control with 100µM H2O2 
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If other substrates are involved, then these typically act as intermediate radicals toward the 
formation of superoxide. The superoxide anion may react further to form hydrogen peroxide, 
which in presence of iron forms highly reactive hydroxyl radicals [86, 131, 224, 225]. Regardless 
of whether Type I or Type II photosensitization occurred, the resulting reactive oxygen then 
react with biomolecules like lipids, nucleic acids etc. to form peroxides leading to a chain 
reaction in the cell organelles causing damage to and potential death of the cell.  
To confirm that the CPNPs are indeed the source of ROS formation in cells upon irradiation with 
light, cells were stained with CellRox Green Reagent (CGR). This reagent is non-fluorescent or 
very weakly fluorescent while in a reduced state and upon oxidation by ROS shows strong green 
fluorescence. Formation of ROS was detected with CGR staining in A549 and OVCAR3 cell 
lines that had taken up CPNPs and were exposed to light, both immediately after in-vitro PDT 
(Figure 4.10D) and 2 hours after PDT was completed (Figure 4.10E). Further confirmation 
comes from the control experiments with CGR staining. Figure 4.10A-C shows three negative 
controls: in absence of the treatment (no particles, no light), in absence of CPNPs with 180J/cm
2
 
light dose, and in absence of photoirradiation with 2 x 10
-4
 mg/ml CPNPs dose, respectively. As 
CGR emission is only detected when full PDT treatment is applied, it can be concluded that the 
CPNPs are the source of ROS under PDT. The data in Figure 4.10B (no particles, 180J/cm
2
 light 
dose) suggest that under the PDT conditions used here no acute phototoxicity occurs, since no 
elevated ROS levels are detected and cell morphology looks normal.  In addition, the data in 
Figure 4.10C (particles, no light) also support the MTT data that CPNP are not acutely cytotoxic, 
since no detectable ROS response is observed in absence of light. 
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 Conclusion 4.3
 
Conducting polymer poly[2-methoxy-5-(2-ethylhexyl-oxy)-p-phenylenevinylene] (MEH-PPV) 
nanoparticles (CPNPs) were studied for application in biophotonics and therapeutics, specifically 
for PDT. The nanoparticles are abundantly taken up by cancer cells while exhibiting promising 
specificity to cancer cells without specific targeting of surface receptors. Cells proliferate 
normally in the presence of CPNPs, indicating the absence of intrinsic cytotoxicity. The bright 
intrinsic fluorescence of the CPNPs is attractive for localization after administering the CPNPs, 
while the large absorption cross section allows the use of low to moderate light levels for ROS 
generation. It was observed that the effectiveness of PDT scales with the extent of CPNP uptake 
and administered light dose. The 2x10
-4 
mg/ml dose of CPNPs under light dose of 180 J/cm
2 
was 
found to be the most effective treatment scheme in-vitro. Promisingly, for the OVCAR3 cell line 
cell viability is near zero under these conditions. 
  
93 
 
 FOLIC ACID CONJUGATED CONDUCTING POLYMER CHAPTER 5
NANOPARTICLES FOR TARGETED PHOTODYNAMIC THERAPY 
 
 Introduction 5.1
 
In the last two decades a steady decrease in cancer patient mortality has been achieved due to 
intensive research and improvements in treatments [226]. However, for high mortality cancers 
such as pancreatic, liver, lung etc. no significant progress has been made [2]. Therefore, a 
multitude of treatment schemes are still being investigated to address existing needs in cancer 
therapeutics. Photodynamic Therapy (PDT) is receiving increasing attention among researchers 
due to its ease of application and promising clinical results [193, 197]. 
In PDT a photosensitizer is administered to tissue and irradiated with visible light matching to 
the absorption spectrum of the photosensitizer [76, 192]. This brings the photosensitizer into its 
singlet excited state, which can then relax to the ground state through different pathways. Decay 
of the excited state by fluorescence makes it possible to use some sensitizers as a tool to locate 
diseased tissue, but only if the photosensitizer is targeted to that tissue. A fraction of the singlet 
excited state of the photosensitizer will intersystem cross to its long lived triplet excited state. 
The triplet state leads to the formation of Reactive Oxygen Species (ROS), highly reactive forms 
of oxygen, which are harmful to cells and can result in cell mortality [75, 78, 79]. The 
mechanism by which the triplet state of the photosensitizer leads to formation of ROS involves 
two types of photooxidative pathways. In type I photooxidation charge transfer from the triplet 
state of the photosensitizer to molecular oxygen yields the reactive superoxide radical ion. 
Alternatively, this process can proceed with biomolecules and solvent molecules in the cells as 
the acceptors to form radicals. In type II photooxidation the triplet state of the photosensitizer 
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transfers energy to the triplet ground state of oxygen to form singlet oxygen [75, 76, 81, 82]. The 
resulting elevated levels of ROS induce oxidative stress and cell death [75, 76, 81, 227, 228].  
When a non-targeted photosensitizer is administered into the body, the patient has to be kept 
away from sunlight in order to avoid toxic side effects. Photosensitizers such as verteporfin, 5-
aminolevulinic acid, and photofrin cause skin diseases that manifest themselves by pigmentation, 
and phototoxic reactions which cause itching and burning sensation, swelling and erythema [125, 
126]. To address such side effects, the photosensitizer must be targeted towards the malignant 
tissue only. Nanoparticle technology has shown promise to improve the efficacy and 
selectiveness of sensitizer delivery towards malignant tissue, causing less side effects. During the 
last decade, monoclonal antibodies (MAbs) have been used to target cancers for diagnosis and 
treatment [229]. In photoimmunotherapy (PIT), MAbs were conjugated with photosensitizers 
such as haematoporphyrin derivative (HpD), chlorin e6 and phthalocyanines to achieve selective 
delivery of the photosensitizer in tumors [229]. However, the current issue with PIT is optimal 
control over the conjugate preparation without changing the biological properties of the 
monoclonal antibodies [229]. Besides targeting cancers through specific antibody/antigen 
interactions, cancer cells can also be targeted by means of the well-documented overexpression 
of receptors such as folate receptors (FR) [176, 230], epidermal growth factor receptors (EGFR) 
[231], Her-2 receptors [232, 233] and others depending on the type of cancer. Ligands specific 
towards these receptors such as folic acid (FA), antibodies Erbitux or Cetuximab, and affibody, 
respectively, can be used for enhanced selectivity of delivery. Research has been reported on 
targeting ovarian cancer with different ligands to make PDT more specific. Recently PDT using 
Fe3O4/Au NPs decorated with 5,10,15,20-tetrakis(4-hydroxyphenyl)-21H,23H-porphine (tHPP) 
as a photosensitizer and affibody for Her-2 specificity to target SK-OV-3 ovarian cancer cells 
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was studied [234]. These NPs were evaluated in xenografted tumor and were found to be very 
effective in showing specificity and inhibition of tumor growth. EGFR targeted PDT using 
liposomes functionalized with Cetuximab as the targeting antibody and benzoporphyrine 
derivative (BPD) as photosensitizer yielded very promising results when applied to ovarian 
cancer cells [116]. Research on the use of folic acid as a ligand for selective delivery of 
photosensitizer in different types of cancer tissues is also well-documented and is still in 
progress. Polymeric micelles conjugated with folic acid to deliver meta-tetra 
(hydroxyphenyl)chlorin (mTHPC) in KB cells in-vitro and corresponding xenografts were 
studied by Syu et al.[117]. CdTe quantum dots acting as a photosensitizer and conjugated with 
folic acid showed specificity to folate receptor (FR) overexpressing KB cells [118]. Similarly, 
zinc tetraaminophthalocyanine (ZnaPc) conjugated with folic acid showed selective delivery of 
the photosensitizer to FR positive (FR+) KB cells [119]. Graphene oxide nanoparticles loaded 
with photosensitizer chlorin e6 (Ce6) and conjugated with folic acid recently showed promise 
when studied in-vitro with MGC803 cells [120].  
Photosensitizers that are currently applied in PDT have moderate extinction coefficients and 
have high singlet oxygen quantum yield, which has provided promising result for PDT treatment 
in clinical settings [235, 236]. Though a lot of work has been completed to improve the 
properties of photosensitizers to make PDT an effective treatment for cancer with only minor to 
no side effects, there still remain a few problems that need to be addressed. These include 1) lack 
of specificity, which leads to side effects such as damage to healthy tissue and prolonged 
photosensitivity of the patient, 2) hydrophobicity of sensitizer molecules that leads to 
aggregation and thus reduced bioavailability and efficacy of the photosensitizer, and 3) dark 
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toxicity of the photosensitizers, which could limit applicability of the photosensitizer, especially 
if non-targeted sensitizers. 
Photosensitizer doped conjugated polymer nanoparticles have recently received attention as next 
generation photosensitizers in PDT. Grimland et al. have recently studied conducting polymer 
nanoparticles acting as nanocarriers encapsulating the photosensitizer tetraphenylporphyrine 
(TPP) [109]. The investigators showed formation of singlet oxygen by UV-vis spectroscopy after 
photoactivating the nanoparticles by one and two photon excitation. As a proof-of-concept DNA 
damage was shown in presence of these nanoparticles. Shen et al. also proved the generation of 
singlet oxygen by tetraphenylporphyrine (TPP) doped in conjugated polymer nanoparticles by 
photoluminescence of singlet oxygen by fluorescence spectroscopy [156]. Similarly, Zhang et al. 
used meta-tetra-(hydroxyphenyl)-chlorin (m-THPC) as the photosensitizer in conjugated 
polymer nanoparticles to form ROS [203]. 
In this article, blended poly[2-methoxy-5-(2-ethylhexyl-oxy)-p-phenylenevinylene] (MEH-
PPV)/Polystyrene Graft Ethylene Oxide functionalized with carboxylic acid (PS-PEG-COOH) 
nanoparticles conjugated with folic acid (FNPs) were studied in-vitro for use in PDT as next 
generation photosensitizers with targeted delivery. The nanoparticles were fabricated by self-
aggregation of the polymer; the only chemistry that was applied was to conjugate folic acid to 
the nanoparticles. The FNPs are not cytotoxic in dark, and are highly effective at producing ROS 
under illumination due to the large extinction coefficient of MEH-PPV (> 10
7
 L mol
-1
 cm
-1
). The 
combination of the hydrophobicity of MEH-PPV, large negative zeta potential of the 
nanoparticles, and receptor mediated uptake resulted in complete selectivity of FNP uptake by 
cancer cell lines that overexpress folate receptors (FR). Among the cancer cell lines studied MIA 
PaCa2 (pancreatic cancer cell line, no FR overexpression) does not show detectable uptake of 
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FNPs, A549 (lung cancer cell line, minor FR overexpression) shows minor FNP uptake, and 
OVCAR3 (ovarian cancer cell line, major FR overexpression) shows abundant FNP uptake. PDT 
results quantified by MTS assay and confirmed by flow cytometry scale with the observed FNP 
uptake as expected. These results indicate the promising nature of this photosensitizer system 
due to its lack of dark toxicity, inclusion of PEG for enhanced circulation times, high rate of 
ROS generation, high cell mortality for the cancer cell line that abundantly overexpresses the 
targeted receptor (OVCAR3), while no cell mortality is observed for non-targeted (TE71 normal 
control and MIA PaCa2) or marginally receptor overexpressing cell lines (A549), and bright 
fluorescence that together with the high degree of selectivity can be used to localize the targeted 
tissue. 
 Results and discussion 5.2
 
 5.2.1 Fabrication, functionalization and characterization of NPs 
 
  Fabrication of FNPs 5.2.1.1
 
The nanoparticles (NPs) to be functionalized were fabricated by the reprecipitation method, 
following a modified procedure from the one published by Wu et al.[237]. In short, a solution of 
2:1 molar ratio of fluorescent hydrophobic polymer MEH-PPV and non-fluorescent comb-like 
amphiphilic polymer PS-PEG-COOH in THF was quickly injected into DI water under vigorous 
stirring. Due to their hydrophobicity, the MEH-PPV polymer chains and the polystyrene 
backbone of PS-PEG-COOH polymer aggregate to form MPNP suspension in water. The 
hydrophilic PEG and COOH parts of the non-fluorescent polymer extend towards water making 
the carboxylic acid groups available on the surface of the MPNPs for further modifications. The 
carboxylic acid groups were then allowed for attachment of ligands to the MPNPs. Scheme 5.1 
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shows the complete process of MPNP fabrication and functionalization by conjugation of folic 
acid to the COOH groups. 
 
Scheme 5.1 Functionalization of MPNPs with folic acid by EDC reaction.  1) Formation of 
MPNPS from mixed solution of MEH-PPV and PS-PEG-COOH in THF, 2) Addition of EDC to 
activate the carboxyl OH groups, forming the O-Acylisourea group on MPNPs, 3) Conjugation 
of folic acid to MPNPs through the formation of an amide bond. 
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After MPNP fabrication NHS and EDC was added to the MPNPs suspension (Scheme 5.1, step 
2) in order to activate the hydroxyl groups of COOH on the MPNPs surface by forming the O-
Acylisourea product, which is a better leaving group. Upon addition of 1:1 molar ratio of folic 
acid to PS-PEG-COOH to the O-Acylisourea product, folic acid conjugates to the MPNPs by 
formation of an amide bond between the amine of folic acid and the carbonyl group of MPNPs 
while replacing the isourea group (Scheme 5.1, step 3). Unreacted folic acid was removed by 
centrifugal filtration. The filtered solution is a suspension of the functionalized NPs (FNPs) in 
water.  
 Characterization by FTIR 5.2.1.2
 
Formation of an amide bond between the carbonyl of MPNPs and amine of folic acid was 
confirmed by FTIR. Figure 5.1A shows the FTIR spectra of MPNPs, FNPs and MEH-PPV NPs. 
Figure 5.1B has the same spectra enlarged from 1000 to 2000 cm
-1
. There are no major 
differences between the spectra of MPNPs and MEH-PPV NPs suggesting that there is no 
chemical bond formation when PS-PEG-COOH and MEH-PPV polymers were mixed with each 
other to fabricate MPNPs. Three particular amide bands in the FTIR spectrum of FNPs (blue 
line), (1) amide I - C=O stretch at 1620 cm
-1
, (2) amide II – NH bend at 1580 cm-1, and (3) amide 
III – 1312 cm-1,confirm that the expected amide bond was formed. There is one primary amine 
(pterine ring) and one secondary amine (p-aminobenzoate moity) in folic acid (Scheme 5.1) 
which can form amide bond with the carbonyl on MPNPs [238, 239]. Chen et al. have recently 
showed that even though the pterine moity in folic acid is essential for the binding affinity to 
folate receptors, they have observed extensive interactions between glutamate group in folic acid 
and side chains of the proteins lining the groove of folate receptors through six hydrogen bonds 
and some backbone interactions [240]. Thus even if the primary amine in the pterine ring is 
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compromised during the conjugation of folic acid to MPNPs, the uptake efficiency would not be 
significantly affected. Also, the conjugation might have occurred through the secondary amine of 
p-aminobenzoate moity of folic acid. The uptake measurements in OVCAR3 cell line (vide infra) 
showed that the uptake efficiency was indeed not compromised.   
 
Figure 5.1 A) FTIR spectra of FNPs (blue line) compared with MEH-PPV NPs (black line) and 
MPNPs (red line). The three particular amide bands at 1620 cm
-1
- (amide I) for C=O stretch, 
1580 cm
-1
 (amide II) for NH bend and 1312 cm
-1
 (amide III) in FNPs spectrum confirm the 
formation of amide bond between amine of folic acid and carbonyl on MPNPs. 
 Zeta potential, UV-vis and fluorescence characterization  5.2.1.3
 
The zeta potential measurements revealed that the MPNPs have a negative zeta potential of -50.8 
± 6.21 mV on them. The high negative charge on MPNPs might be due to the COOH groups 
protruding out on the surface of MPNPs. This also confirms the assumption that the hydrophilic 
parts of PS-PEG-COOH extends out on the surface of MPNPs. The FNPs also have a zeta 
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potential of -48.9 ± 8.36 mV due to few conjugated folic acid molecules and the unreacted 
COOH groups on the surface of FNPs (Table 5.1).   
The optical properties of the MPNPs and FNPs were measured by UV-vis and fluorescence 
spectroscopy (Figure 5.2A and B). The UV-vis spectra (Figure 5.2A) of the MPNPs (black line) 
and FNPs before centrifugal filtration (red line) have max 497 nm while the max  of FNPs after 
centrifugal filtration (blue line) is blue shifted by 5 nm and has max at 492 nm. The blue shift in 
the max might be attributed to compacting of the FNPs and collapse of polymer chains within the 
FNPs when residual THF is extracted from the FNPs during the centrifugal filtration. The 
collapse of the polymer chains inside the FNPs leads to severe kinking and bending of 
conjugated backbone of polymers which results in reduced conjugation length leading to the blue 
shift in absorption spectra [127, 241-243]. 
The fluorescence spectra (Figure 5.2B) of MEH-PPV have max at 589 nm, even though the 
fluorescent intensity of the FNPs after filtration is drastically reduced to 40 %. This effect again 
can be attributed to the removal of THF during centrifugal filtration. When THF is removed the 
FNPs may become compacted, which can result in lowered quantum efficiency of fluorescence 
due to self-quenching [244]. 
The presence of folic acid in FNPs suspension was confirmed by acquiring emission of folic acid 
by exciting the FNPs at 300 nm (Figure 5.2C). The fluorescence spectrum of folic acid in FNPs 
before filtration (red line) has max at 402 nm. After filtration the fluorescence intensity of folic 
acid in FNPs (blue line) decreases as the unreacted folic acid is removed from the solution, 
although the max remains unaltered. 
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Figure 5.2 A) UV-vis spectra of NPs suspended in water. The absorption maxima for MPNPs 
and FNPs before filtration are 497 nm. After filtration the absorption maximum shifts to 491 nm. 
NP fluorescence spectra were collected for excitation at B) MEH-PPV absorption and C) folic 
acid absorption. The max of emission spectra in B) for the three different NPs is 589 nm, 
although the intensity of fluorescence is reduced to approximately 40 % after filtration. In C) the 
fluorescence of folic acid has max at 402 nm. After filtration the observed intensity of folic acid 
fluorescence is reduced due to removal of unreacted folic acid from FNP solution. 
 
It has been previously been reported that MEH-PPV NPs fabricated by the reprecipitation 
method have a diameter of about 35 nm in diameter [127]. When MPNPs were fabricated from a 
mixture of 2:1 molar ratio of PS-PEG-COOH and MEH-PPV by the reprecipitation method, the 
size was measured to be 45.12 ± 4.60 nm by DLS (Table 5.1). After folic acid conjugation the 
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size of FNPs before filtration decreased slightly to 39.81 ± 5.12 nm as compared to MPNPs. 
After filtration the size of FNPs increased to 68.80 ± 7.30 nm, which is attributed to aggregation 
of a few FNPs. 
Table 5.1 shows the size of NPs determined by DLS and the zeta potential on their surfaces. For 
the unfiltered FNPs zeta potential data could not be obtained due to the free folic acid and excess 
NHS and EDC present in solution.   
 
 
 Atomic force microscopy 5.2.1.4
 
 
Figure 5.3 AFM images of MEH-PPV NPs, MPNPs and FNPs showing the size of the 
nanoparticles 
 
 MPNPs FNPs(unfiltered) FNPs(filtered) 
DLS (nm) 45.12±4.60 39.81±5.12 68.80±7.30 
Zeta 
Potential 
(mV) 
-50.8 ± 6.21 - -48.9 ± 8.36 
 
 
MEH-PPV NPs- 27.3±6.7 nm FNPs- 93.7±9.3 nmMPNPs- 35.1±5.2 nm
100 nm 100 nm 200 nm
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The AFM data collected on MEH-PPV NPs, MPNPs and FNPs showed the sizes for these 
nanoparticles as shown in Figure 5.3 
 
 5.2.2 Uptake of NPs in cell lines: 
 
As the zeta potential on the surfaces of FNPs is -48.9±8.36 mV, it was expected that due to such 
a high negative charge there would be no or limited non-specific uptake of FNPs in any of the 
cell lines [166, 168, 174, 245]. Due to the presence of folic acid on FNPs, it was speculated that 
regardless of the high negative charge on the surfaces of FNPs, a receptor mediated uptake of 
FNPs would occur in cell lines which overexpress folate receptors (FRs) on their cell 
membranes. Figure 5.4 shows the qualitative uptake of FNPs in OVCAR3, A549, MIA PaCa-2, 
and TE 71 cell lines by epiluminescence imaging. As it is well known that over 90% of ovarian 
cancer cells overexpress FRs [176, 246-249], and the expression of FRs on ovarian carcinoma is 
very homogenous [250], OVACR3 cell line was selected as the FR positive (FR+) cell line to 
observe the specific or receptor mediated uptake of FNPs. The expression of FRs in A549 is 
marginal at best, if not absent [249, 251-259], while in MIA PaCa-2 cell line there are receptors 
other than FRs (FR-), like thrombin receptors [260] or EGFR [261]. Thus these two cancer cell 
lines were chosen as negative controls. TE 71 cell line was chosen as a control normal cell line 
which has marginal to no FRs. It was observed that when all the four cell lines were incubated 
with 2 x 10
-4
 mg/ml dose of FNPs, the uptake of FNPs was highest in OVCAR3 due to high 
amount of FRs expressed in this cell line, while in A549 the uptake of FNPs was limited as it has 
few to no FRs . MIA PaCa-2 and TE 71 have no detectable fluorescence suggesting no uptake of 
FNPs in these cell lines. To rule out the possibility of non-specific uptake in OVCAR3 or in 
A549, all the cell lines were incubated with equal dose of MPNPs which are not conjugated with 
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folic acid (Figure 5.4). It was observed that there was no detectable fluorescence from MPNPs in 
any of the four cell lines suggesting that there was no non-specific uptake of MPNPs. This 
observation infers that for receptor mediated uptake of NPs, presence of FRs on cell membranes 
and presence of folic acid on NPs surface was necessary.  
 
Figure 5.4 Uptake of FNPs in OVCAR3, A549, MIAPaCa2 and TE 71 cell lines. The 
fluorescence images represent FNPs fluorescence (green) and DAPI fluorescence (blue). The 
corresponding phase contrast images are also shown. The left column shows the control images, 
the middle column shows images for cells treated with MPNPs and the right column shows 
images for cells treated with FNPs. 
 
To determine the selectivity of FNP uptake, flow cytometry was performed on the cell lines after 
incubating them with a 2 x 10
-4
 mg/ml dose of FNPs. Figure 5.5 shows the flow cytometry 
results. TE 71, MIA PaCa-2 and A549 data show that 0% cell population has uptaken FNPs, 
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while for the OVCAR3 cell line 85% of the cell population has uptaken FNPs. Although 
epiluminescence imaging shows small amounts of FNPs in A549 cells, flow cytometry was 
unable to detect this fluorescence. In addition, PDT did not induce cell mortality in this case 
(vide infra). The selectivity of the FNPs towards OVCAR3, which is the folate overexpressing 
cell line, is easily explained by the conjugation of the FNPs with folic acid, while the limited 
uptake by A549 is attributed to the few FRs available on the cell surface. In addition, the lack of 
uptake by the other cell lines can be attributed to the hydrophobicity and the high negative zeta 
potential of the FNPs, which makes non-receptor mediated uptake unlikely.   
 
Figure 5.5 Uptake of FNPs quantified by flow cytometry for A) TE 71, B) MIA PaCa-2, C) 
A549, and D) OVCAR3. Red line- normalized percent population of control cells, Green line- 
normalized percent population of cells incubated with FNPs. E) Bar graph indicating the 
percentage of the cell population that has uptaken FNPs compared to the control (no FNPs). F) 
Bar graph indicating the average fluorescence intensity of FNPs detected for the different cell 
lines. 
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 5.2.3 Intrinsic cytotoxicity of FNPs: 
 
 
Figure 5.6 Intrinsic cytotoxicity of FNPs quantified by MTS viability assay for A) TE 71, B) 
MIA PaCa-2, C) A549, and D) OVCAR3 cell lines incubated with different doses of FNPs and 
kept in dark. MTS assays were run up to 96 hours after incubation with FNPs. 
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The cytotoxicity of the FNPs in dark (intrinsic cytotoxicity) was studied by quantifying the 
proliferation of the cell lines in presence of FNPs by MTS cell viability assay. Data are shown in 
Figure 5.6 for TE 71, MIA PaCa-2, A549 and OVCAR3 cell lines. For each cell line the % cell 
viability at each FNPs dose is normalized to the control dose. Cell viability was observed to be 
about 100% at each dose of FNPs up to 96 hours. No cell mortality is observed for the TE 71 and 
MIA PaCa-2 cell lines, which at first glance appears trivial due to the lack of FNP uptake. 
However, the presence of the FNPs in the cell culture media also did not result in cell mortality. 
For A549 limited FNP uptake was observed, while for OVCAR3 abundant FNP uptake occurred 
(Figure 5.4). Again, in neither case cell mortality is observed. The FNPs clearly do not affect the 
normal functioning of cells, and cells in the presence of FNPs proliferate normally. 
 
 5.2.4 Generation of oxidative stress in cells after PDT: 
 
It is well known that when conducting polymers absorb light, it can intersystem cross and form 
triplet excited states. In case of MEH-PPV the probability of intersystem crossing and forming 
triplet excited states is 1.25% [220]. These triplet states can dissipate to the ground state by 
energy transfer to triplet ground state of molecular oxygen to form the highly reactive singlet 
oxygen (type I photooxidation) [75, 76, 81, 82]. In other instances, charge transfer can occur to 
molecular oxygen to form superoxide or to other substrates such as solvent molecules and 
biomolecules (lipids, DNA, nucleic acids etc.) to form radicals (type II photooxidation) [75, 76, 
81, 82]. The reactive superoxide radicals then form hydrogen peroxide by grabbing an electron 
which in presence of Fe (II) can form hydroxyl radicals [86, 130, 224, 225]. The hydroxyl 
radicals lead to lipid peroxidation and cause damage to cell organelles [86]. Thus it was 
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hypothesized that MEH-PPV, upon photoexcitation would effectively photosensitize the 
formation of singlet oxygen or superoxide radicals, and that FNPs would not require a 
photosensitizing dopant.  
The generation of ROS in cells treated with FNPs and irradiated with light, i.e. PDT experiment, 
was detected by CellRox Green reagent (CGR). CGR has weak to no fluorescence in its reduced 
form. When CGR is oxidized by ROS in the cells, it displays bright green fluorescence. Figure 
5.7D shows epiluminescence images of OVCAR3, A549, MIA PaCa2 and TE 71 cell lines 
administered with 2 x 10
-4
 mg/ml FNPs and photoirradiated with 180 J/cm
2
 of light. After PDT 
the cells were incubated for 2 hours before staining with CGR. The CGR fluoresces bright green 
only in the OVCAR3 cell line as only OVCAR3 has uptaken FNPs and so ROS are generated 
only in this cell line turning the CGR color bright green. Even though the A549 cell line has 
shown small amounts of FNP uptake (Figure 5.4), that amount is not sufficient to produce ROS 
detectable by CGR. MIA PaCa2 and TE 71 cell lines show no emission from CGR as there was 
no uptake of FNPs, hence no ROS formation.  
The fact that ROS formation in the cells is due to PDT and not intrinsic cytotoxicity of FNPs 
such as previously observed for, for instance, quantum dots, which lead to elevated ROS even in 
absence of light [210, 211], was confirmed by performing three negative controls stained with 
CGR shown in Figure 5.7A-C (A) in absence of PDT (no FNPs, no light), B) in absence of FNPs 
with 180 J/cm
2
 light dose, and C) in absence of light with 2 x 10
-4
 mg/ml FNPs dose). As no 
emission from CGR was observed in Figure 5.7B, it can be concluded that there is no ROS 
formation in absence of FNPs and that the light dosage alone did not form ROS. Thus, there is no 
phototoxicity up to the 180 J/cm
2
 light dose. The phase contrast images show that the light has 
no adverse effect on the morphology of the cells. Figure 5.7C show no CGR emission in any of 
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the four cell lines when the cells are administered with FNPs but are not irradiated with light. 
This confirms that ROS is not formed when the FNPs are not photoactivated. This is also a 
confirmation test for the negative results of the intrinsic cytotoxicity by MTS assay when cells 
are kept in dark (Figure 5.6). These negative controls show that FNPs if uptaken by the cells and 
exposed to light are the source of ROS formation, hence the oxidative stress in the cells. Figure 
5.7E is the positive control for formation of ROS in which all the cell lines are treated with 
100µM H2O2.  
 
Figure 5.7 Detection of ROS generated after PDT in TE 71, MIA PaCa-2, A549 and OVCAR3 
cell lines.  A) negative control (no FNPs, no light), B) negative control with 180 J/cm
2
 (no FNPs) 
indicates no photocytotoxicity is observed, C) negative control with 2 x 10
-4
 mg/ml FNPs (no 
light) indicates no intrinsic cytotoxicity, D) 2 hours post-PDT , E) positive control with 100 µM 
H2O2.  Green color in (C) is fluorescence of FNPs. Green color in E and F is GreenRox dye 
oxidized due to presence of ROS 
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 5.2.5 Quantitative measurements on cell viability after PDT: 
 
The quantitative effect of PDT on the studied cell lines was measured by MTS cell viability 
assays. Figure 5.8 shows the % cell viability after PDT. For each cell line the viabilities at the 
three different FNPs doses (0.4 x 10
-4
 mg/ml, 2 x 10
-4
 mg/ml and 3.6 x 10
-4
 mg/ml) is compared 
with the viability at the control FNPs dose (0 mg/ml). MTS assay was performed immediately 
after PDT (0 hours) and 4 hours post-PDT to evaluate further progression after PDT (Figure 5.8). 
It was shown previously that with the use of composite MEH-PPV/PCBM NPs for PDT, 4 hours 
is a sufficient time to cause nearly 100% cell mortality [262]. The measurements revealed that 
the viability of TE 71, MIA PaCa-2 and A549 cell lines is almost 100%. In OVCAR3 cell line, 
the viability decreases with increase in FNPs dose. It is a well-accepted fact that 90% of ovarian 
cancer cells overexpress FRs [176, 246-249], and the expression of FRs on ovarian carcinoma is 
very homogenous [250]. Therefore, OVCAR3 cell line is considered as the FR+ cancer cell line. 
Due to this there is receptor mediated uptake of the folic acid conjugated nanoparticles 
preferentially in ovarian cancer cells [263, 264]. In A549 the expression of FRs is marginal 
although not completely absent [176, 230, 265]. In MIA PaCa2 there is no FR overexpression 
[260] [261] and so this is considered as the FR- cancer cell line. The TE 71 cell line has very less 
to no FR expression and is the normal control cell line. Due to high overexpression of FR in 
OVCAR3 the uptake of FNPs is abundant through receptor mediated endocytosis. As the FNPs 
dose increases the amount of FNPs uptaken by the OVCAR3 cells increases. At the same time 
the population of cells that uptake FNPs also increases. This increase in amount of FNPs in many 
cells leads to formation of more ROS in the large number of cells, which reflects in low percent 
cell viability. In MIA PaCa2 due to absence of FR expression, no FNPs uptake occurred and so 
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the viability is almost 100%. In A549 due to less FR expression there is small uptake of FNPs 
(Figure 5.4). 
 
Figure 5.8 MTS cell viability assay to quantify result from PDT for TE 71, MIA PaCa-2, A549 
and OVCAR3 cell lines incubated with different doses of FNPs and irradiated with 3 doses of 
light. The post-PDT incubation time is 0 and 4 hours. 
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But the amount of FNPs is not sufficient for formation of oxidative stress in A549 cell line. Thus 
the viability is approximately 100%. The TE 71 which also has less to no overexpression of FRs 
on their plasma membranes, there is no uptake of FNPs and cell viability is 100%. Also, as the 
light dose increases (60 J/cm
2
, 120 J/cm
2
 and 180 J/cm
2
) the cell viability in OVCAR3 cell line 
decreases implying a larger amount of ROS formation with higher dose of light.  
 
 5.2.6 Quantification of PDT results by flow cytometry: 
 
The pathway through which cell death occurs depends on 1) the photosensitizer and cell line 
combination, 2) the PDT dosage and 3) the subcellular or subtissular localization of the 
photosensitizer. Luo et al. showed that when photosensitizer chloroaluminum phthalocyanine 
dispersed throughout the cytoplasm 90% of murine leukemia P388 cells underwent apoptosis at 
low light dosage [266]. At higher dosage of light more membrane photodamage was observed, 
which was found to inhibit apoptosis. Jori et al. have shown that PDT with zinc phthalocyanine 
(ZnPc) photosensitizer in MS-2 fibrosarcoma induced random necrotic and apoptotic cell deaths 
due to different subcellular and/or subtissular distribution of the photosensitizer [267]. Here, PI 
and annexin V FITC staining was completed after PDT with 4 hours of post-PDT incubation to 
evaluate cell death efficiency and pathways by flow cytometry. Flow cytometry data are shown 
in Figure 5.9. The annexin V FITC fluorescence intensity is plotted on the x-axis and the PI 
fluorescence is plotted on the y-axis. The red dots correspond with the control samples while the 
black dots correspond with samples treated with PDT. The lower left quadrant in the dot plots 
show cells which are viable. The lower right quadrants indicate cells which are positive for 
annexin V-FITC, but negative for PI indicating apoptotic cells.  
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Figure 5.9 Flow cytometry to quantify cell mortality after PDT. Dot plots are for  A) TE 71, B) 
MIA PaCa-2, C) A549 and D) OVCAR3 cell lines stained with FITC annexin V and PI. The red 
dots are the cells from control and the black dots are the cells from PDT experiment. The four 
quadrants in each plot are labeled for live (lower left), apoptotic (lower right), necrotic (upper 
left) and dual stained cells (upper right) along with percentages in each quadrant. The data are 
plotted as bar graphs for clarity in E-H. E) Percent cell viability in each cell line after PDT, F) 
Percent of necrotic cells in each cell line after PDT, G) Percent of apoptotic cells after PDT, and 
H) Relation between % cell population with FNPs and % cell death after PDT in each cell line. 
In each bar graph the percentages are compared with the corresponding control experiments. 
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The upper left quadrants show the fraction of the cell population exhibiting only PI fluorescence, 
indicating necrotic cells. The cell population in the upper right quadrant is dual stained by 
annexin V-FITC and PI. Looking at the flow cytometry data for PDT (black dots) in OVCAR3 
cell line (Figure 5.9D), almost 75% of the cells are dual stained, 14 % cells are stained by PI only 
(necrotic) and 6 % cells are stained by annexin V-FITC (apoptotic)..   
For the dual stained cells, it is difficult to distinguish the cell death pathway. Arguments can be 
made that the cells have undergone either apoptotic death, or necrotic death, or a random 
combination of necrotic and apoptotic death. The first possibility is that the cells have gone 
through apoptotic death, which would give a positive signal for fluorescence of annexin V-FITC. 
Since these are in-vitro experiments there is no mechanism of phagocytosis to destroy the 
apoptotic cells, which allows the cells go into the apoptotic necrosis stage. At this stage the cells 
become permeable to PI stain and as a result become dual stained. The second possibility is that 
the cells have gone through necrosis, which would give a positive signal for fluorescence of PI. 
After cell death non-specific binding of annexin V-FITC to the cells becomes possible so that the 
cells get stained with annexin V-FITC as well and show up in the dual stained quadrant of the 
flow cytometry data. The third possibility is that different cells might have undergone both 
necrotic or apoptotic deaths randomly to form a mixed population of apoptotic and necrotic cells.  
For clarity the flow cytometry data was also plotted as bar graphs as shown in Figure 5.9E-H. It 
can be seen from Figure 5.9E that the percentage of live cells in all the cell lines but OVCAR3 is 
almost same as the control (no PDT) and that there is no death because of PDT as these cell lines 
have not uptaken FNPs. On the other hand, in OVCAR3 cell line the percent of live cells is only 
5. These data are very consistent with the data obtained by MTS cell viability assay (Figure 5.8). 
Thus flow cytometry and MTS cell viability both confirm the effect of PDT on the cell lines 
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studied here. The MIA PaCa2 cell line was found to be very sensitive to handle during culture 
and was the reason of showing approximately 85% live cells in both control and PDT 
experiment. The OVCAR3 cell line has 14% necrotic cells (Figure 5.9F) while only 6.5% 
apoptotic cells (Figure 5.9G). The percent of dead cells is shown in Figure 5.9H. OVCAR3 has 
almost 75% of dead cells. The % cell death in OVCAR3 cell line can be directly related to the % 
cell population which has uptaken FNPs (green bars in Figure 5.9H).The % cell population 
which has uptaken FNPs is 84. When PDT is performed on these cells, the % cell death is 75 and 
can be directly related to the formation of ROS which leads to death. Figure 5.10 shows the 
representative image of OVCAR3 cell line showing apoptotic and necrotic cells stained with 
annexin V FITC ad PI depicting random combination of apoptosis and necrosis in the sample 
after PDT.  
 
Figure 5.10 Representative image of OVCAR3 cell line stained with PI, annexin V FITC and 
DAPI after PDT is given to the cells. the image shows apoptotic and necrotic cells.  
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 Localization of FNPs using Endosome and lysosome dyes  5.3
 
 
Figure 5.11 OVCAR3 cells administered with FNPs and stained with 1) Early endosome dye and 
2) lysosome dye for localization of FNPs inside the cells. 
 
FNPs were localized by using the early endosome and lysosome dyes. From the figure it can be 
seen that the FNPs are neither in the lysosomes nor in the early endosomes. This observation 
might be due to energy transfer occurring from dye to polymer bleaching the dye, hence making 
it harder to co-localize the polymer nanoparticles and lysosomes or endosomes. More work 
needs to be done to localize the FNPs in cells, which could throw light on the uptake pathway.  
 
 Conclusion 5.4
 
Blended MEH-PPV/PS-PEG-COOH nanoparticles conjugated with folic acid (FNPs) were 
studied in-vitro for use in PDT as next generation photosensitizers with targeted delivery. The 
FNPs were found to be selectively targeting cancer cell lines that overexpress folate receptors 
 
Phase Contrast                           Dye fluorescence                         FNPs fluorescence                          Dye + FNPs  
Ly
so
tr
ac
ke
r
En
d
o
tr
ac
ke
r
1
2
A B C D
118 
 
(FR) and exhibited no dark toxicity. In-vitro PDT experiments show near complete cell mortality 
for the cancer cell line that abundantly overexpresses the targeted receptor (OVCAR3) while no 
cell mortality is observed for non-targeted (TE71 normal control and MIA PaCa2) or marginally 
receptor overexpressing cell lines (A549).  The high extinction coefficient, effective ROS 
generation, high degree of uptake selectivity, absence of dark toxicity, inclusion of PEG which 
may enhance circulation times for in-vivo applications, and observation of cell mortality only for 
abundantly receptor overexpressing target cell line indicate the promising nature of this 
photosensitizer system for targeted PDT.   
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 CdS:Mn/ZnS QDOT BIOSENSING PROBE CHAPTER 6
 
 Introduction  6.1
 
In order to develop an understanding of the mechanisms by which cells perform functions in 
normal and diseased situations, it is necessary to have knowledge of the biological environments 
and the processes that occur in the cells at the molecular level. Processes that need to be 
understood at the molecular level involve signaling pathways, migration of ions, protein 
activities, and biomolecular interactions [268, 269]. Drug discovery and delivery is governed by 
these questions as well. Such knowledge can ultimately aid in the design of new drugs, to deliver 
these drugs in right amount, and selectively at the diseased sites [270, 271]. Biosensors are an 
attractive tool to detect, image and quantify processes at molecular level. In a biosensor an 
analyte such as a biomolecule or an ion is detected by combining a biological component with a 
physical or chemical detector. Various biosensors have been reported and are still under study 
that can report on biomolecular events.  
Small molecules have been employed in the task of sensing biomolecules [272, 273]. 
Biomolecules such as glutathione, cysteine and homocysteine have been successfully detected 
in-vitro by using MeO BODIPY-Cl molecules [274]. Reaction with thiol groups in biomolecules 
lead to fluorescence turn-on in BODIPY. DNA based biosensors have also been designed to 
detect DNA hybridization, microRNA, and DNA damage. DNA biosensors are based on 
different types of sensing mechanisms such as optical, electrochemical and piezoelectric 
properties [275, 276]. Genetically encoded fluorescent biosensors have been developed to image 
and study protein activity and to observe small molecule signals and bimolecular interactions. 
These biosensors use light emitting proteins to quantify protein activity or ligand binding 
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through 1) FRET (fluorescence resonance energy transfer) measurements between a donor 
protein (cyan fluorescent protein) and an acceptor protein (yellow fluorescent protein) [277-279], 
2) spectral shift when a ligand binds to a protein [280, 281], and 3) by translocating within the 
cell to get information on membrane lipids and biomolecules involved in signaling [282]. 
Aptamer based colorimetric biosensors can detect a wide variety of molecules such as Hg
2+
, 
dopamine vitamin B12 etc. [283-287]. Nanomaterials such as, chitosan-carbon nanotube system, 
(FITC-dextran) and (Rh-ConA) system have been used to detect glucose electrochemically and 
by FRET mechanism respectively [288-290]. CdSe/ZnS quantum dots (Qdots) and gold (Au) 
nanoparticles in which the Qdot was coordinated with Au nanoparticles through β-secretase 
(BACE1) substrate peptide- Ni-nitrilotriacetate (Ni-NTA) conjugation, was used in-vitro for 
sensing the BACE1 enzyme by a quenching and restoration mechanism through distance 
dependent fluorescence resonance energy transfer (FRET) [291]. Surface plasmon resonance 
(SPR) biosensors  have shown promise due spectral sensitivity of their localized surface plasmon 
resonance (LSPR) to nanoenvironments [292-296]. 
While these biosensors have resulted in impactful discoveries in developing our understanding of 
molecular biology events in living systems, there are instances where analytical and shuttling 
capabilities are needed. A particularly urgent example is drug delivery, where information on the 
timing, localization and quantification of drug delivery in the intracellular environment is 
typically missing. Nanoparticle biosensors have the potential to provide an answer for such 
questions. Quantum dots (Qdots) have a size similar to that of a protein, exhibit bright 
fluorescence and are photostable. These characteristics make Qdots excellent candidates for 
developing a biosensor, and as a result Qdots have received considerable attention as biosensing 
platforms [72, 73, 291, 297-303] that could advance our understanding of biomolecular events in 
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living systems. Quenching of Qdots has been exploited to develop biosensors for quantification 
of analyte. Citrate-capped Mn-modified CdSe/CdS Qdots were developed to detect tinidazole in 
tablets and injections. The fluorescence of the Qdots quenched with increasing concentration of 
tinidazole.[303]. Similarly, fluorescence quenching of GSH capped CdTe/CdS Qdots by 
sanguinarine in aqueous solution was investigated to quantify sanguinarine in synthetic samples 
and fresh urine samples in healthy humans [301]. While fluorescence quenching schemes have 
brought tremendous progress in biosensing, the sensitivity of biosensors can be significantly 
elevated by observing fluorescence restoration of a quenched state. Qdot fluorescence restoration 
from a quenched (OFF) state to a bright (ON) state is particularly useful due to the ease of 
detecting fluorescence emission of Qdots. Positively charged porphyrine has been shown to 
quench negatively charged thioglycolic acid capped CdTe quantum dots (CdTe-TGA Qdots) via 
electron transfer. It was found that calf thymus DNA (ctDNA) restores the fluorescence via 
electron transfer mechanism, allowing for its detection by CdTe-TGA Qdots. Fluorescence 
restoration occurs when porphyrins are removed from the Qdot surface and bind to ctDNA 
interfering the electron transfer process between porphyrins and Qdots [302]. The same scheme 
was used for ruthenium anticancer drug instead of porphyrine [72]. Detection of metal ions in 
water has been reported as well. The ligand 1,10-phenanthroline was used to turn off Qdot 
fluorescence by photoinduced hole transfer. Blocking of the hole transfer by formation of a metal 
ion-phenanthroline complex restores the Qdot fluorescence in a concentration dependent manner 
[298].  
In the past few years, dopamine has been studied as a ligand that can quench Qdot fluorescence 
due to its redox properties, specifically the ability to adopt catechol and quinone forms. Medintz 
et al. have used CdSe/ZnS Qdots conjugated with a peptide-dopamine moiety to investigate the 
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pH dependency of Qdot fluorescence quenching. At low pH dopamine is in its hydroquinone 
(catechol) form and is a poor electron acceptor, resulting in bright Qdot fluorescence. When the 
pH was increased, oxidation of hydroquinone leads to the formation of quinone form of 
dopamine, which is a good electron acceptor. Thus electron transfer from Qdots to quinone leads 
to quenching of the Qdot fluorescence. This pH sensing probe was applied to measure the 
intracellular pH. [73, 299]. The Nadeau group has applied a fluorescence restoration scheme to 
track CdSe/ZnS Qdot-dopamine probes in-vitro based on the redox properties of dopamine as 
quenching ligand [300]. Fluorescence restoration was achieved by photooxidation during optical 
imaging. Banerjee et al. reported CdS:Mn/ZnS-dopamine conjugates and proposed to use it for 
detecting intracellular GSH[297]. 
In this article the in-vitro properties of activatable (OFF/ON) dopamine-CS2 conjugated 
CdS:Mn/ZnS Qdots were investigated to determine the potential for application as an intra-
cellular optical biosensor. The uptake and fluorescence restoration of Qdots to ON state in 
OVCAR3 and A549 cell lines was confirmed by confocal microscopy and single particle 
spectroscopy. Our findings give a promising proof of concept for the probe design. 
 Results and discussion 6.2
 
 6.2.1 MMCNP with NAC as the linker 
 
 Probe design  6.2.1.1
 
Multifunctional/multimodal composite activatable nanoprobe (MMCNP) for optical tracking of 
intracellular release of therapeutic drugs was developed. In addition to optical based tracking, the 
MMCNP is integrated with MR imaging modality and selective cancer targeting functionality. 
Briefly, MMCNP consists of a super-paramagnetic iron oxide (SPIO; ~ 20 nm size) core and 
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satellite CdS:Mn/ZnS quantum dot (Qdots; 3.5 nm size) shell (Scheme 6.1). Each Qdot is 
attached to core SPIO by a single hetero-bifunctional cross-linker molecule, dihydrolipoic acid 
(DHLA). Next, an N-Acetyl-L-Cysteine (NAC) modified STAT 3 inhibitor (NAC-STAT3; a 
therapeutic model drug), a NAC modified folate (NAC-FA; a cancer targeting agent) and a NAC 
modified ethylenediamine (NAC-EDA, an amine modified ligand) were separately synthesized. 
The Qdot surface was then decorated with NAC-STAT3, NAC-FA and finally with NAC-EDA. 
The surface amine groups were reacted with N-hydroxysuccinimide (NHS) ester derivative of 
methyl-poly-ethylene glycol (MPEG-NHS ester; a biocompatible highly-hydrophilic dispersing 
agent) to improve overall dispersibility of the MMCNPs. 
 
Scheme 6.1 Schematic representation of MMCNP in OFF state and ON state. Qdots are attached 
to iron IONP. STAT3, folic acid and PEG are attached to these Qdots. When MMCNP reacts 
with GSH the sulfur bonds between Qdots and IONP and between Qdots and drug are broken, 
thus restoring fluorescence of Qdots. 
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As expected, significant quenching of luminescence was observed once SPIO-Qdots are 
conjugated to NAC-STAT3. Further quenching was observed upon treatment with NAC-FA. It 
was noted that NAC itself did not quench Qdot luminescence, thus justifying the role of STAT 3 
and FA as quenchers. The MMCNP is thus essentially in fluorescently quenched (“OFF”) state. 
The luminescence of MMCNPs could be restored (“ON” state) upon treatment with an 
appropriate agent that could effectively cleave disulfide bonds. Glutathione (GSH)[304], a 
tripeptide biomolecule found in all animal cells at relatively high cytosolic concentration (~ 
5mM, reduced form), is a powerful electron donor. It effectively reduces disulfide bonds of 
cytoplasmic proteins to cysteines and gets converted to glutathione disulfide, its oxidized form. 
The design of MMCNPs is such that once it is exposed to intracellular glutathione environment, 
it would be disintegrated by GSH. This forms the basis of intracellular tracking of STAT3 
release as shown in Scheme 6.1.  
 Fluorescence restoration in solution with GSH 6.2.1.2
 
Fluorescence of MMCNPs is restored (“ON” state) in solution in about 30 minutes upon 
interaction with GSH (λexc = 375 nm and λem = 588 nm) and about 5 fold increase in fluorescence 
intensity is observed at 10 mM GSH concentration (Figure 6.1A). A systematic time-dependent 
fluorescence restoration study was also conducted. Results showed that 2mM concentration of 
GSH is sufficient to restore fluorescence completely in about an hour (Figure 6.1B).  
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Figure 6.1 Fluorescence restoration of MMCNPs. A) restoration with 10 mM GSH with time, B) 
graph showing 2 mM GSH is sufficient for complete restoration.   
 
 Fluorescence restoration at particle level wiith intracellular GSH 6.2.1.3
 
 
Figure 6.2 A) Bright field, B) Corresponding epi-luminescence laser microscopy images of 
MDA-MB-231 cells incubated with MMCNPs for 5 h C) Normalized ensemble fluorescence 
emission spectra acquired by sample scanning laser confocal microscopy under 375 nm laser 
excitation. 
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Confocal based imaging and spectroscopic studies were conducted for MMCNPs (drop casted 
and air-dried) on a microscope slide.  Fluorescence image and ensemble fluorescence emission 
spectra of MMCNPs (“OFF” state, background signal) were recorded before and after the 
addition of GSH solution (2 mM) (Figure 6.2C). It was observed that fluorescence brightness 
exponentially increased. This is due to the restoration of fluorescence (“ON” state) from 
MMCNPs, a direct evidence of release of quenchers. Fluorescence spectrum was significantly 
broadened. Such broadening of emission spectrum is likely due to GSH induced aggregation of 
Qdots. MDA-MB-231 cells after 5 hours incubation with folated MMCNPs showed similar 
broadening of luminescence spectrum and aggregation of Qdots, thus confirming the formation 
of GSH coated Qdots in cytosolic environment. Interestingly, majority of aggregated Qdots were 
found near the cell membrane Figure 6.2B. It is expected that zwitterionic interaction among 
GSH coated Qdots will not only reduce the surface area (increase in particle size) but also 
significantly reduce surface polarity, thus increasing hydrophobicity. Such hydrophobic Qdots 
aggregates will thus have tendency to accumulate close to cell membrane with reduced polar 
environment. 
 6.2.2 Qdot-dopamine probe with CS2 linker  
 
 Probe design 6.2.2.1
 
The goal of the work reported here is to design an activatable (OFF/ON) dopamine-CS2 
conjugated CdS:Mn/ZnS Qdot biosensor and evaluate the in-vitro properties to determine the 
potential for application as an intracellular optical biosensor. The probe in this study consists of 
Mn doped CdS/ZnS core/shell (CdS:Mn/ZnS) quantum dots modified by CS2-dopamine 
conjugates on its surface (Scheme 6.2).  
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Scheme 6.2 Illustration of the process to synthesize the OFF probe and subsequent fluorescence 
restoration (ON probe). A) The dopamine-CS2 conjugate is prepared, and B) is attached to bare 
Qdots to form the OFF probe. Addition of GSH to the OFF probe restores the fluorescence of 
Qdots as GSH displaces the dopamine-CS2 conjugate. 
 
During the fabrication of the OFF probe, in the first step the primary amine of dopamine forms a 
stable carbodithioate product with CS2. The disulfide moiety on this product then couples with 
the ZnS shell of the CdS:Mn/ZnS Qdots as shown in Scheme 6.2. The CS2 molecule achieves the 
necessity of zero length covalent coupling of dopamine to the Qdots, facilitating electron transfer 
processes between Qdots and dopamine in the probe that are at the basis of the OFF/ON sensing 
mechanism. Dopamine is a well-known redox-active neurotransmitter that reversibly switches 
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between a reduced state (catechol) and an oxidized state (benzoquinone), and quenches the Qdot 
fluorescence by acting as electron donating or accepting moiety, resulting in the OFF state. 
Glutathione (GSH), which is present in the intracellular environment, can displace the dopamine 
ligand from the Qdot surface, thereby restoring fluorescence to the ON state (Scheme 6.2).  
 
 Probe characterization 6.2.2.2
 
6.2.2.2.1 FTIR  
 
The FTIR spectrum of bare Qdots in Figure 6.3A and C has no distinct peaks except the broad 
OH band at 3300 cm
-1
 due to the Zn(OH)2 formed on the Qdot crystal surface during the 
crystallization process of ZnS semiconductor. The second important peak at 1589 cm
-1
 due the 
C-S band confirms the presence of 19% AOT determined by thermogravimetric analysis (data 
not shown).  
When the dopamine-CS2 conjugate attaches to Qdots, the bare Qdot spectrum changes 
significantly suggesting the Qdots are coated with dopamine-CS2 (Figure 6.3A and C OFF 
probe), whereas the dopamine aromaticity seems to be lost due to the charge transfer processes 
occurring between Qdots and the dopamine aromatic ring. Peaks that reflect aromaticity of 
dopamine are not present in the data for the OFF probe (Figure 6.3B and D). The aromatic C=C 
stretches at 1616 cm
-1
, 1600 cm
-1
, 1499 cm
-1
and 1472 cm
-1
 present in pure dopamine cannot be 
seen in the OFF probe. Also, the out-of-plane aromatic C-H bend at 814 cm
-1 
has disappeared for 
the OFF probe. The aromatic C-O stretch at 1284 cm
-1 
in dopamine now appears to be smaller in 
the OFF spectrum while the 1260 cm
-1
 peak has disappeared completely. The aromatic C-H 
stretches at 3070 cm
-1
 and 3039 cm
-1
, which can be seen embedded in the broad OH band in pure 
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dopamine are not observed in OFF probe FTIR spectrum. The 3338 cm
-1
 peak for the N-H 
stretch of the primary amine in dopamine now shifts to 3377 indicating a secondary amine is 
present in the OFF probe.  
 
Figure 6.3 A) FTIR spectra of OFF probe, ON probe, and bare Qdot samples. B) FTIR spectra of 
dopamine and GSH. C) and D) are the FTIR data from A) and B), respectively, expanded in the 
absorption ranging from 2000 to 650 cm
-1
. 
 
This secondary amine is due to the bond formation between -NH2 of dopamine and CS2. New 
peaks also appear in the data collected for the OFF probe. Strong C=S stretches can be seen at 
1589 cm
-1
, 1133 cm
-1
 and at 1042 cm
-1
. The medium bands at 1213 cm
-1 
and 1167 cm
-1 
are due to 
the C-N stretch and appear for pure dopamine as well as for the OFF probe. The peaks at 1146, 
1113 and 1080 cm
-1 
for dopamine belong to the C-N stretches and are buried under the strong CS 
stretch at 1133 cm
-1
 observed for the OFF probe. The peak at 878 cm
-1
 due to N-H wagging 
persists for both dopamine and the OFF probe. 
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When GSH is added to the OFF probe, it displaces the dopamine-CS2 conjugate from the Qdot 
surface. The FTIR spectrum of the ON probe shows very similar features to bare Qdots and GSH 
(Figure 6.3B and D). No peaks related to dopamine are observed, which suggest that the 
dopamine is removed from the surface of the Qdots. The only difference between the FTIR data 
of pure GSH and GSH located on the Qdot surface is the S-H stretching band at 2522 cm
-1
 
present for pure GSH. When GSH displaces dopamine, the hydrogen from S-H is replaced by the 
Qdot surface and the 2522 cm
-1
 band disappears for the ON probe. The C-S stretches can be seen 
at 1589 cm
-1
 for the ON probe. The presence of GSH on the Qdot surface is also confirmed by 
the observation of the amide I, II and III at 1519, 1506 and 1395 cm
-1 
respectively for ON probe. 
 
6.2.2.2.2 HRTEM 
 
HRTEM characterization of OFF and ON probes, shown in Figure 6.4A and B, reveals the size 
of a single Qdot crystal to be approximately 5 nm with lattice planes for CdS 101 and ZnS 110 
(insets top left) [305]. HRTEM showed no changes in Qdot crystal structure of ON and OFF 
probes. SAED data confirm the presence of the CdS core and ZnS shell with lattice spacings of 
3.19 Å and 1.95 Å, respectively. EDX data confirm the presence of the Qdot in both samples 
with no change in the elemental composition of the probe. 
DLS measurements reveal large cluster sizes for the ON and OFF probes. The OFF probe cluster 
size ranges from 75nm to 1µm, while after GSH treatment (ON probe) a size range of 230nm to 
1µm is found. The OFF probe tends to aggregate in aqueous suspension due to the presence of 
hydrophobic dopamine on the Qdot surface. After GSH addition, similar observations were 
made. It is possible that the clusters formed by the OFF probe persist for the ON probe  
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Figure 6.4 High Resolution Transmission Electron Microscopy of (A) OFF probe and (B) ON 
probe together with Selective Area Electron Diffraction (insets bottom right). Lattice spacing 
remains consistent for both samples. Inner spacing and outer spacing are 3.14 Å and 1.95Å, 
respectively. Diffraction patterns do not significantly change.  The top left inset shows that 
lattice planes can be seen for Qdot crystals of both samples (corresponding to yellow circles in 
panels A and B). 
 
 Optical characterization 6.2.2.3
 
6.2.2.3.1 Uv-vis and Fluorescence solution spectroscopy 
 
Optical characterization was completed on the OFF and ON probe, as well as bare Qdots and 
bare Qdots treated with GSH as controls. The bare CdS:Mn/ZnS Qdots show broad structureless 
absorption from the UV range to 500 nm (Figure 6.5A). The addition of GSH to bare Qdots 
increases the absorption in the UV range only. Functionalizing the bare Qdot with dopamine 
results in both a characteristic dopamine peak at 278nm, as well as increased absorption in the 
UV range for the OFF probe compared to bare Qdots. When GSH is added to the OFF probe, the 
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278nm dopamine peak becomes slightly suppressed, suggesting that the physical interaction 
between the Qdot core and dopamine-CS2 was interrupted.   
The fluorescence spectrum of bare Qdots depicted in Figure 6.5B (black line) shows the 
characteristic 589 nm peak representative of the 
4
T1-
6
A1  transition of the Mn
2+
 dopants in Qdots 
[306, 307]. Excitations in the CdS [306] decay nonradiatively to the Mn
2+
 unoccupied 3D states 
via energy transfer, from where the d-d transition (
4
T1-
6
A1) leads to the orange fluorescence 
[306, 307]. This emission peak remains unchanged even after dopamine is covalently conjugated 
to the ZnS shell of the Qdots. However, the fluorescence intensity of Qdots is quenched by 90% 
(red line) as compared to the bare Qdots. Dopamine present in reduced (catechol) or oxidized 
(quinone) form can quench the Qdots by electron transfer processes between dopamine and 
Qdots. In reduced form of dopamine the electron transfer occurs from dopamine catechol ring to 
Qdots quenching the Qdots fluorescence [299, 300, 308] while in oxidized form of dopamine the 
electron transfer occurs from Qdots to dopamine quinone ring [299, 300, 308]. When GSH is 
added to this OFF Probe, immediate fluorescence restoration up to 50% is observed (blue line) 
without any shift in peak emission wavelength, which remains at 589 nm. It is expected that the 
disulfide bond of dopamine-CS2 conjugate is displaced by the sulfur of GSH restoring the 
fluorescence of Qdots [297]. The fluorescence of bare Qdots was decreased by 10% when GSH 
was added to it, suggesting that GSH has minimal quenching effect on Qdots. Surface exchange 
of Qdots between GSH and covalently linked CS2-dopamine is a reversible process as both 
molecules are capable of bonding with the Qdots through sulfide bonds. This also explains the 
reason for not getting 100% fluorescence restoration.  
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Figure 6.5 A) Absorption spectra showing bare Qdots, bare Qdots treated with GSH, the OFF 
probe, which exhibits a peak at 278nm peak consistent with dopamine absorption and the ON 
probe, which shows decreased absorption at the 278 nm peak. B) Fluorescence spectra were 
recorded at 375nm excitation. All Qdot samples show the characteristic peak emission from the 
Mn
2+ 
dopant. Fluorescence restoration was observed after interaction of the OFF probe with 
GSH.   
 
Figure 6.6 shows data from a time-lapse study that tracks restoration of Qdot fluorescence for 30 
minutes while GSH interacts with the probe. The restoration occurs within 15 seconds after 
addition of GSH to the OFF probe. Qdot fluorescence intensity keeps increasing rapidly up to 5 
minutes and after which it keeps increasing steadily by small increments upto 15 minutes and 
then plateaus after 15 minutes. 
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Figure 6.6 Time lapse restoration curve showing the fluorescence restoration of Qdots occurs 
within 15 seconds after addition of GSH to the OFF probe. The data point at 0 min is the 
fluorescence intensity of OFF probe. 
 
6.2.2.3.2 Single particle spectroscopy  
 
For detailed studies on the optical properties of the OFF probe and to evaluate the effect of GSH 
on the OFF probe, single particle (aggregate) spectroscopy was performed.  
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Figure 6.7 Single particle spectroscopy on bare Qdots, OFF probes, and ON probes (after 
restoration of OFF probes by extracellular GSH). A) Ensemble spectra for new batch of probes 
with catechol form of dopamine. B) Ensemble spectra for old batch of probes with quinone form 
of dopamine. Each panel shows single particle ensemble spectra for bare Qdots (blue line), OFF 
probe (black line) and ON probe (red line). C) A model is shown detailing possible charge 
transfer pathways that result in OFF state probes.  Pathways considered are from the catechol 
ring of dopamine to the Qdot core of the probe (Pathways A1, A2, A3, and A4) and from the 
Qdot core of the probe to the quinone form of dopamine (Pathways B1 and B2).The pathways 
A1 and B1 shown in yellow are the most probable electron transfer pathways. 
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For this the bare Qdots, the OFF probe and the ON probe (after addition of GSH to OFF probe) 
samples were drop cast on glass substrates and dried in vacuum. Two different batches, a new 
batch not exposed to oxygen and an old batch oxidized in air, were studied. Single particle 
fluorescence data for the two batches of probes are shown in Figure 6.7A and B, respectively. In 
both graphs, the ON and OFF probe single particle ensemble spectra are compared with the bare 
Qdot spectra. For the new batch, the ensemble spectrum of the OFF probe shows quenched 
fluorescence, with a decrease in fluorescence intensity by 90%. The ensemble spectrum of the 
ON probe shows 60% fluorescence restoration after GSH addition. For the aged oxidized batch 
the OFF probe spectrum shows only 30% quenching, while the brightness of the ON state is near 
90% compared of the bare Qdots intensity. The prominent peak at 500 nm observed in the OFF 
probe spectrum of the oxidized samples, which is absent in the data of pristine samples, 
corresponds with the emission of oxidized dopamine [73, 300, 308]. The possibility of assigning 
this peak to Qdot emission was discarded as CdS and ZnS emit at 525 nm and 550 nm [309, 
310]. The absence of this peak in the ON spectrum in Figure 6.7B indicates removal of dopamine 
after addition of GSH to the OFF probe. For both samples the peak emission of bare Qdots is red 
shifted from 589 nm in solution (Figure 6.5B) to 610 nm. This red shift can be attributed to 
drying and aggregation of Qdots as the samples were drop casted and dried before imaging. For 
both the oxidized and pristine samples a shoulder can be seen at 650 nm for the OFF and ON 
probes as seen from the normalized data shown in Figure 6.8. This emission is typically 
indicative of defects on the Qdot core [310]. However, the pristine Qdot does not show a 
noticeable shoulder while the oxidized bare Qdots again exhibit the shoulder at 650 nm. In 
addition, the data in Figure 6.7B show that the intensity of this shoulder increases from bare 
Qdots to OFF probe to ON probe. These observations indicate that ligand attachment introduces 
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defects on the Qdot surface, besides the defect formation induced by oxidation. It is probable that 
electrons become trapped in these defects, which could affect the process of electron transfer 
from Qdots to the quinone form of dopamine. This may explain the lowered magnitude of 
quenching for old batches of probe as can be seen in Figure 6.7B. Alternatively, the quinone 
form of dopamine may not be an efficient quencher.  
 
Figure 6.8 Normalized fluorescence spectra showing the 650 nm shoulder in ON and OFF probes 
in new batch, while in old batch the 650 nm shoulder can be seen increasing from bare Qdots to 
OFF probe to ON probe.  
 
The quenching of Qdot fluorescence is attributed to electron transfer processes between Qdot 
and dopamine. Whether the transfer is from or to the Qdots depends on the oxidation state of the 
dopamine attached to it. Electron transfer occurs from dopamine to Qdots when dopamine is in 
its reduced form (catechol), while electron transfer occurs from Qdots to dopamine when 
dopamine is in the oxidized form (quinone). A model for these electron transfer mechanisms in 
CdS:Mn/ZnS-dopamine probe is represented in Figure 6.7C, and mirrors the model proposed for 
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CdSe/ZnS-dopamine conjugates [299]. In the case of CdS:Mn/ZnS-dopamine the electron 
transfer from the reduced catechol ring of dopamine could occur to the 
4
T1 level of Mn
2+
 (A3), 
but this process may be less likely since excitons migrate from the Qdot core to the Mn
2+
 d states 
via energy transfer within a few picoseconds to block that pathway [306, 311, 312]. The process 
of electron transfer from catechol to the valence band of CdS (A2) might be blocked for the same 
reason, although the rate of this process is unknown. The electron transfer process from catechol 
to conduction band of CdS can happen (A4), but Qdot may not result in quenching unless the 
electron quickly moves on to the 
4
T1 level of Mn
2+
. The most plausible electron transfer that 
results in fluorescence quenching is from the catechol excited state to the 
6
A1 state of Mn
2+
 (A1). 
The electron can recombine with holes in the Mn
2+
 valence band, subsequently quenching the 
emission. The long-lived orange transition 
4
T1 to 
6
A1 state has a lifetime on the order of 1 to 2 
ms, which makes this process more probable to occur.  When the quinone form of dopamine is 
involved, electron transfer may occur from the 
4
T1 level of Mn
2+
 (B1) or from the CdS 
conduction band (B2) to the unoccupied molecular orbital of the quinone ring of dopamine. The 
B2 process may be less likely since exciton migration from Qdots to Mn
2+
 d states occurs on the 
picosecond scale. Conversely, as the life time of 
4
T1 state is 1-2 ms, the B1 process seems more 
likely to happen.  
 
 In-vitro evaluation  6.2.2.4
 
6.2.2.4.1 Epiluminescence and confocal microscopy  
 
The intracellular behavior of the probe was studied with A549 human lung cancer, OVCAR3 
human ovarian cancer and TE 71 normal mouse epithelial cell lines. Figure 6.9 shows the 
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epiluminescence images of these three cell lines incubated with the probe for 24 hours. The red 
spots in the images indicate the probe inside the cells. No probe fluorescence was detected for 
the TE 71 control cell line; while there is detectable fluorescence of the probe in the A549 and 
OVCAR3 cell lines. Overall, very small amounts of uptake can be seen in cancer cell lines. This 
limited uptake by cancer cell lines can be attributed to the aggregation of the probe in aqueous 
media together with the absence of dopamine receptors on the cell surfaces.  
 
Figure 6.9 Overlaid epiluminescence and phase contrast images for A549, OVCAR3 and TE 71 
cell lines incubated with and without probe. The bright red (false color) spots localize the ON 
probe, indicating that the probe is inside the cells, which is confirmed by confocal microscopy. 
Qdots appear to be in the ON state for cancer cell lines, while no fluorescence was detected in 
the TE 71 cell line, suggesting no detectable uptake occurred for the latter. Faint emission can be 
detected in regions on the substrate away from cells, suggesting these probes remained in the 
OFF state.     
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In case of the cells which express dopamine receptors, the reduced form of dopamine is bound to 
the dopamine receptors on cells by hydrogen bonds between hydroxyl groups on catechol form 
of dopamine and serins on the receptor [313, 314]. However, none of the cell lines studied herein 
have dopamine receptor overexpression. This rules out the possibility of dopamine (catechol) 
related specific uptake of probes. Still, the oxidized form of dopamine (quinone) is bound by the 
sulphhydryl of cysteines present in several proteins located on the cell membrane [313, 315]. 
Thus it is possible that oxidized dopamine ligands on the Qdot probe facilitate cysteine mediated 
uptake. Another reason of having very small amount of uptake is that the probes have limited 
dispersibility in aqueous environment. This may lead to precipitation of probes from DMEM 
media, leading to limited availability to cells. The OFF probe can be seen outside the cells with 
very low fluorescence as shown in Figure 6.9. The bright red spots on the cells can be considered 
as ON state probe as the intracellular GSH detaches the dopamine from Qdots restoring its 
fluorescence. While the details on the uptake mechanism of probes by the different cell lines are 
yet to be understood, it is reasonable to claim that particles eventually end up in the cytosolic 
environment. This statement is supported by the fact that probe restoration requires GSH, which 
is present in the cytosol. 
To confirm that the probe is uptaken by the cells and is not stuck on the cell wall confocal 
fluorescence microscopy was performed on OVCAR3 cell line which was administered with 
0.05 mg/ml of probe. The slices were acquired at 0.3 µm for a height of 6.3 µm. The image in 
the Figure 6.10 shows the z stack of the composite of DIC and fluorescence images. The z stack 
confirms that the probe is inside the cell.  
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Figure 6.10 3D confocal imaging of an OVCAR3 cell confirms that the Qdot probe entered the 
cell, corroborated by the bright fluorescence (ON state, false color). 
 
6.2.2.4.2 Intracellular single particle spectroscopy 
 
The intracellular single particle spectroscopy was performed on the same samples of A549 and 
OVCAR3 cells for which epiluminescence imaging was completed. Figure 6.11A and C show 
the confocal fluorescence raster scan images of OVCAR3 and A549 cells. Figure 6.11B and D 
 
142 
 
show the ensemble spectra acquired for these images. The fluorescence images are the overlay of 
the autofluorescence of cells (shown in grey false color) and fluorescence of probe (shown in red 
false color). Each ensemble spectrum is an average of 50 spectra acquired on multiple cell 
images. 
Figure 6.11B and D shows that OVCAR3 cells have autofluorescence max at 482 nm while 
A549 cells autofluoresces with peak emission at 473 nm. The OFF probes have low fluorescence 
intensity as expected due to the quenching of Qdot fluorescence by the attached dopamine 
ligands. These spectra were acquired from the red spots outside the cells. The max for these 
spectra are at 587 nm (OVCAR3) and 593 nm (A549) with a blue shoulder around 475 nm which 
is attributed to autofluorescence of the cells. The presence of an autofluorescence peak in the 
OFF state probe indicates that the probe is stuck on the cell membrane and is not exposed to the 
cytosolic environment. The ensemble spectrum of the ON probe in OVCAR3 (Figure 6.11B) has 
max at 623 nm, which is 36 nm red shifted as compared to the OFF probe. The ensemble 
spectrum of the ON probe in A549 (Figure 6.11D) has max at 610 nm, which is 17 nm red 
shifted as compared to OFF probe. The fluorescence intensity is almost doubled in the ON state 
spectra for both the cell lines. This is due to the detachment of dopamine from the OFF probe 
upon interaction with intracellular GSH, indicating that the probe has entered the cell and has 
been exposed to the cytosolic environment. Broadening and red shifts observed for the ON 
spectra in both the cell lines can be attributed to the aggregation of Qdots inside cells and also to 
the increase in defects or sulfur vacancies in the Qdots. In addition, when comparing the data for 
the ON probe observed for the A549 and OVCAR 3 cell lines, the intensity of the shoulder at 
650 nm is noticeably higher for the OVCAR3 case. The mechanism behind this observation is 
not fully understood at this time and will require further study.  
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Figure 6.11 Single particle spectroscopy on Qdot probes that entered OVCAR3 and A549 cells, 
i.e. ON state. Representative images of A) OVCAR3 and C) A549 cells constructed by 
overlaying the autofluorescence (grey, false color) acquired by using a 480/30 band pass filter 
and probe fluorescence (red, false color) collected by 585/20 band pass filter. Image size is 50 
µm. Ensemble fluorescence spectra (the average of 50 spectra collected from multiple cells) of 
the ON probe in the intracellular environment were collected for the B) OVCAR3 and D) A549 
cell lines. The ON probe in OVCAR3 cells has max at 623 nm (black line) which is 36 nm red 
shifted as compared to the OFF probe in OVCAR3 cells (red line), which has its max at 587 nm. 
The autofluorescence of OVCAR3 cells (blue line) is at max 482 nm. For A549 the 
autofluorescence max is at 473 nm. In A549 cells the ON probe has max at 610 nm which is 17 
nm red shifted compared to max 593 nm of the OFF probe. 
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Potentially, this observation suggests that the Qdots internalized by OVCAR3 have either 
developed more defects or are more strongly aggregated, possibly in larger clusters.   
 
 Conclusion  6.3
 
The development of a CdS:Mn/ZnS biosensor that can use the redox properties of dopamine to 
detect the intracellular drug delivery events was achieved. Conjugation of dopamine ligand to 
CdS:Mn/ZnS Qdots through carbon disulfide (zero length coupling) efficiently quenched the 
Qdot fluorescence through electron transfer processes between Qdots and dopamine. The 
electron transfer occurs from or to Qdots depending on attachment of oxidized form of dopamine 
(quinone) or reduced form dopamine (catechol) respectively. The fluorescence was restored up 
to 60% by extracellular GSH in which the sulfide bonds from dopamine-CS2 conjugation were 
replaced by sulfide bonds from GSH. The intracellular GSH Qdot restored the Qdot fluorescence 
by releasing dopamine moiety inside the cells, thus giving a promising proof of concept for the 
probe design.  . 
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